var title_f33_53_34640="Tacrolimus: Pediatric drug information";
var content_f33_53_34640=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tacrolimus: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/51/4921?source=see_link\">",
"       Tacrolimus (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/9/26772?source=see_link\">",
"       Tacrolimus (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12822 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-71969A6E96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34640=[""].join("\n");
var outline_f33_53_34640=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?4/51/4921?source=related_link\">",
"      Tacrolimus (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?26/9/26772?source=related_link\">",
"      Tacrolimus (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_53_34641="Left atrial myxoma TTE TEE II";
var content_f33_53_34641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68725&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left atrial myxoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long axis precordial view from a transthoracic echocardiography shows the tumor as a vague mass just behind the aortic root (panel A). The apical four chamber view (panel B) shows the mass attached to the interatrial septum. A transesophageal echocardiography (panels C and D) reveals that the myxoma is highly mobile and at surgery, the tumor had the consistency of jelly and fragmented easily.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34641=[""].join("\n");
var outline_f33_53_34641=null;
var title_f33_53_34642="Cerebriform connective tissue nevus plantar foot";
var content_f33_53_34642=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Cerebriform connective tissue nevus of the plantar foot is classic for Proteus syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permisison from: the Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34642=[""].join("\n");
var outline_f33_53_34642=null;
var title_f33_53_34643="Urine sediment showing a hyaline cast";
var content_f33_53_34643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F86339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F86339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urine sediment showing a hyaline cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 387px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Representative photomicrographs of unstained elements in urine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Brunzel NA. Fundamentals of urine and body fluid analysis, 2nd ed, WB Saunders, Philadelphia, 2004. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34643=[""].join("\n");
var outline_f33_53_34643=null;
var title_f33_53_34644="WPW ablation site during OAVRT";
var content_f33_53_34644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Mapping of Wolff-Parkinson-White during an orthodromic atrioventricular reciprocating tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three surface ECG leads (I, II, and V1) and intracardiac electrograms recorded from the high right atrium (HRA), the bundle of His (HIS), the ablation (ABL) catheter, and the right ventricular apex (RVA). During an orthodromic atrioventricular reciprocating tachycardia (OAVRT) there is retrograde atrial activation via the accessory pathway, which is located in the area where ventriculoatrial (VA) conduction time is the shortest, ie, at HIS 2-1 where the conduction time is 78 ms. Also noted on ABL 2-1 is the fusion of the V and A electrograms, which precedes the atrial electogram on the HIS bundle catheter, making this site a good choice for ablation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34644=[""].join("\n");
var outline_f33_53_34644=null;
var title_f33_53_34645="Liposomal cytarabine: Drug information";
var content_f33_53_34645=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Liposomal cytarabine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/14/25828?source=see_link\">",
"    see \"Liposomal cytarabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F156098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DepoCyt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F156099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      DepoCyt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F156116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Antimetabolite (Pyrimidine Analog)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F156102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note: Initiate dexamethasone 4 mg twice daily (oral or I.V.) for 5 days, beginning on the day of cytarabine liposomal administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Lymphomatous meningitis: I.T.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Induction:",
"     </i>",
"     50 mg every 14 days for a total of 2 doses (weeks 1 and 3)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Consolidation:",
"     </i>",
"     50 mg every 14 days for 3 doses (weeks 5, 7, and 9), followed by an additional dose at week 13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     50 mg every 28 days for 4 doses (weeks 17, 21, 25, and 29)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F156103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F5017165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If drug-related neurotoxicity develops, reduce dose to 25 mg. If toxicity persists, discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F156079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension, intrathecal [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DepoCyt&reg;: 10 mg/mL (5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F156063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F156082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For intrathecal use only. Dose should be removed from vial immediately before administration (must be administered within 4 hours of removal). An in-line filter should",
"     <b>",
"      NOT",
"     </b>",
"     be used. Administer directly into the CSF via an intraventricular reservoir or by direct injection into the lumbar sac. Injection should be made slowly (over 1-5 minutes). Patients should lie flat for 1 hour after lumbar puncture.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F156080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of lymphomatous meningitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F156123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cytarabine may be confused with clofarabine, Cytosar&reg;, Cytoxan, vidarabine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cytarabine liposomal may be confused with conventional cytarabine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       <i>",
"        Intrathecal medication safety:",
"       </i>",
"       The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson, 2009) encourage the following safety measures for intrathecal chemotherapy:",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Intrathecal medication should not be prepared during the preparation of any other agents",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; After preparation, store in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"       &bull; Delivery to the patient should only be with other medications also intended for administration into the central nervous system",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F156114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Chemical arachnoiditis (without dexamethasone premedication: 100%; with dexamethasone premedication: 33% to 42%; grade 4: 19% to 30%; onset: &le;5 days); headache (56%), confusion (33%), fever (32%), fatigue (25%), seizure (20% to 22%), dizziness (18%), lethargy (16%), insomnia (14%), memory impairment (14%), pain (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dehydration (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (46%), vomiting (44%), constipation (25%), diarrhea (12%), appetite decreased (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (12%), thrombocytopenia (3% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (40%), back pain (24%), abnormal gait (23%), limb pain (15%), neck pain (14%), arthralgia (11%), neck stiffness (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Tachycardia (9%), hypotension (8%), hypertension (6%), syncope (3%), edema (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Agitation (10%), hypoesthesia (10%), depression (8%), anxiety (7%), sensory neuropathy (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia (7%), hyponatremia (7%), hyperglycemia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (9%), dysphagia (8%), anorexia (5%), hemorrhoids (3%), mucosal inflammation (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Incontinence (7%), urinary retention (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (10%), contusion (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness (10%), tremor (9%), peripheral neuropathy (3% to 4%), abnormal reflexes (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Hypoacusis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (10%), cough (7%), pneumonia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% (Limited to important or life-threatening): Anaphylaxis, bladder control impaired, blindness, bowel control impaired, cauda equine syndrome, cranial nerve palsies, CSF protein increased, CSF WBC increased, deafness, encephalopathy, hemiplegia, hydrocephalus, infectious meningitis, intracranial pressure increased, myelopathy, neurologic deficit, numbness, papilledema, somnolence, visual disturbance",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F156085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cytarabine or any component of the formulation; active meningeal infection",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F156067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chemical arachnoiditis:",
"     <b>",
"      [U.S. Boxed Warning]: Chemical arachnoiditis (nausea, vomiting, headache, fever) occurs commonly; may be fatal if untreated. The incidence and severity of chemical arachnoiditis is reduced by coadministration with dexamethasone; dexamethasone should be administered concomitantly with cytarabine (liposomal) to diminish chemical arachnoid symptoms.",
"     </b>",
"     Hydrocephalus has been reported and may be precipitated by chemical arachnoiditis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Meningitis: Infectious meningitis may be associated with intrathecal administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: May cause neurotoxicity (including myelopathy), which may lead to permanent neurologic deficit (rare); monitor for neurotoxicity. Reduce subsequent doses; discontinue with persistent neurotoxicity. The risk for neurotoxicity is increased when administered with other antineoplastic agents or with cranial/spinal irradiation. Persistent (extreme) somnolence, hemiplegia, visual disturbances (including blindness; may be permanent), deafness, cranial nerve palsies, peripheral neuropathy, and even combined neurologic features (cauda equina syndrome) have been reported. CSF flow blockage may lead to increased  free cytarabine concentrations in the CSF and increase the risk for neurotoxicity; assess CSF flow prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For intrathecal use only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician. Facilities appropriate for diagnosis and management of complications should be readily available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intrathecal safety: Intrathecal medications should not be prepared during the preparation of any other agents. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as \"intrathecal\" use only. Delivery of intrathecal medications to the patient should only be with other medications intended for administration into the central nervous system (Jacobson, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F156072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F156075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F156086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproductive studies have not been conducted with cytarabine liposomal. Cytarabine, the active component, has been associated with fetal malformations when given as a component of systemic combination chemotherapy during the first trimester. Systemic exposure following intrathecal administration of cytarabine liposomal is negligible; however, women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F156107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4936523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although the systemic exposure following intrathecal administration of cytarabine liposomal is negligible, breast-feeding is not recommended due to the potential for serious adverse reactions in the nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (DepoCyt Intrathecal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (5 mL): $3145.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F156077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor closely for signs of an immediate reaction; neurotoxicity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F156087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Depocyte (AT, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F156066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cytarabine liposomal is a sustained-release formulation of the active ingredient cytarabine, an antimetabolite which acts through inhibition of DNA synthesis and is cell cycle-specific for the S phase of cell division. Cytarabine is converted intracellularly to its active metabolite cytarabine-5&rsquo;-triphosphate (ara-CTP). Ara-CTP also appears to be incorporated into DNA and RNA; however, the primary action is inhibition of DNA polymerase, resulting in decreased DNA synthesis and repair. The liposomal formulation allows for gradual release, resulting in prolonged exposure.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F156084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Systemic exposure following intrathecal administration is negligible since transfer rate from CSF to plasma is slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, CSF: 6-82 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, CSF: Intrathecal: &lt;1 hour",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cole BF, Glantz MJ, Jaeckle KA, et al, &ldquo;Quality-of-Life-Adjusted Survival Comparison of Sustained-Release Cytosine Arabinoside Versus Intrathecal Methotrexate for Treatment of Solid Tumor Neoplastic Meningitis,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2003, 97(12):3053-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/53/34645/abstract-text/12784341/pubmed\" id=\"12784341\" target=\"_blank\">",
"        12784341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia-Marco JA, Panizo C, Garcia ES, et al, &ldquo;Efficacy and Safety of Liposomal Cytarabine in Lymphoma Patients With Central Nervous System Involvement From Lymphoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2009, 115(9):1892-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/53/34645/abstract-text/19235254/pubmed\" id=\"19235254\" target=\"_blank\">",
"        19235254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Glantz MJ, LaFollette S, Jaeckle KA, et al, &ldquo;Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1999, 17(10):3110-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/53/34645/abstract-text/10506606/pubmed\" id=\"10506606\" target=\"_blank\">",
"        10506606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jabbour E, O&rsquo;Brien S, Kantarjian H, et al, &ldquo;Neurologic Complications Associated With Intrathecal Liposomal Cytarabine in Combination With High-Dose Methotrexate and Cytarabine to Patients With Acute Lymphocytic Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(8):3214-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/53/34645/abstract-text/17209054/pubmed\" id=\"17209054\" target=\"_blank\">",
"        17209054",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson JO, Polovich M, McNiff KK, et al, &ldquo;American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/53/34645/abstract-text/19786650/pubmed\" id=\"19786650\" target=\"_blank\">",
"        19786650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jaeckle KA, Batchelor T, O'Day SJ, et al, &ldquo;An Open Label Trial of Sustained-Release Cytarabine (DepoCyt) for the Intrathecal Treatment of Solid Tumor Neoplastic Meningitis,&rdquo;",
"      <i>",
"       J Neurooncol",
"      </i>",
"      , 2002, 57(3):231-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/53/34645/abstract-text/12125986/pubmed\" id=\"12125986\" target=\"_blank\">",
"        12125986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spina M, Chimienti E, Martellotta F, et al, &ldquo;Phase 2 Study of Intrathecal, Long-Acting Liposomal Cytarabine in the Prophylaxis of Lymphomatous Meningitis in Human Immunodeficiency Virus-Related non-Hodgkin Lymphoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2010, 116(6):1495-501.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/53/34645/abstract-text/20108270/pubmed\" id=\"20108270\" target=\"_blank\">",
"        20108270",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9500 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-71A5527948-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34645=[""].join("\n");
var outline_f33_53_34645=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708677\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156098\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156099\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156116\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156102\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156103\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795925\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795926\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5017165\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156079\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156063\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156082\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156080\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156123\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156114\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156085\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156067\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299115\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156072\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156075\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156086\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156107\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4936523\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323089\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156077\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156087\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156066\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F156084\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9500\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9500|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?25/14/25828?source=related_link\">",
"      Liposomal cytarabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_53_34646="Culture-negative endocarditis";
var content_f33_53_34646=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Culture-negative endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34646/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34646/contributors\">",
"     Didier Raoult, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34646/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34646/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34646/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34646/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34646/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/53/34646/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis (IE) remains a diagnostic challenge in some patients. Identification of the etiologic agent is critical to select an appropriate treatment, as the fatality rate remains high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/1\">",
"     1",
"    </a>",
"    ]. The proportion of IE that is without an etiologic diagnosis varies from country to country and among different centers in the same country. These variations reflect the local epidemiology of IE, diagnostic criteria used, initiation of antibiotics in patients prior to obtaining blood cultures, and the diagnostic protocol used to establish an etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology and microbiology of culture-negative endocarditis will be reviewed here. Criteria for the diagnosis of IE and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of blood culture-negative IE varies by country and host, as exposure to infection with highly fastidious bacteria (many zoonotic) or fungi depends on whether the organism is endemic to the area and whether the host is particularly susceptible to infection with the organism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood culture-negative IE is defined as endocarditis without etiology following inoculation of at least three independent blood samples in a standard blood culture system with negative cultures after seven days of incubation and subculturing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures remain negative in two to seven percent of patients with IE even when the utmost care is taken in obtaining the proper number and volume of blood cultures and patients with prior antibiotic treatment are excluded; the frequency is higher in patients who have already been treated with antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cultures are negative in endocarditis for three major reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous administration of antimicrobial agents",
"     </li>",
"     <li>",
"      Inadequate microbiological techniques",
"     </li>",
"     <li>",
"      Infection with highly fastidious bacteria or nonbacterial pathogens (eg, fungi)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of culture-negative IE varies by country, with a higher proportion of culture-negative IE in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/6-13\">",
"     6-13",
"    </a>",
"    ]. The variability in incidence is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case series from Algeria found 62 of 110 (56 percent) cases of IE were culture-negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar rate was found in South Africa, 26 of 47 (55 percent), and in Pakistan, 32 of 66 (48 percent) patients with definite IE were culture-negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 10-year national prospective survey in the Slovak Republic found that 133 of 339 (39 percent) cases of IE were culture negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A two-year multicenter prospective study in Italy found 37 of 147 (25 percent) patients with a definite diagnosis of IE by Duke criteria were culture-negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case series from Sweden identified 116 of 487 (24 percent) episodes of IE were culture-negative; however, if patients who had received antibiotic treatment were excluded, the proportion of culture-negative IE was 64 of 487 (13 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second study from Spain addressed the differences in rates of culture-negative endocarditis in patients with or without previous antibiotics; rates in patients who did or did not receive antibiotic treatment were 20 of 107 (19 percent) compared to six of 107 (6 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case series from Japan noted 170 of 848 (20 percent) patients with IE were culture-negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case series from France reported 79 of 427 (18.5 percent) patients with IE were culture-negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case series from the United Kingdom found that 63 of 516 (12 percent) cases with IE were culture-negative [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differences in frequency of culture-negative IE in countries reflect the increased incidence of fastidious zoonotic agents (eg, Bartonella spp, Coxiella burnetii, or Brucella spp) causing human infection in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/8\">",
"     8",
"    </a>",
"    ], the differences in microbiologic techniques, and perhaps, the availability of antibiotics without prescription in some countries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for culture-negative endocarditis include the risk of exposure to fastidious organisms including zoonotic agents, underlying valvular heart disease, right-sided endocarditis, and the presence of a pacemaker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/13,15-17\">",
"     13,15-17",
"    </a>",
"    ]. Culture-negative IE due to Aspergillus has also been reported in a patient with a left ventricular assist device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Possible etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HACEK organisms (",
"    <strong>",
"     H",
"    </strong>",
"    aemophilus aphrophilus [subsequently called Aggregatibacter aphrophilus and Aggregatibacter paraphrophilus];",
"    <strong>",
"     A",
"    </strong>",
"    ctinobacillus actinomycetemcomitans [subsequently called Aggregatibacter actinomycetemcomitans];",
"    <strong>",
"     C",
"    </strong>",
"    ardiobacterium hominis;",
"    <strong>",
"     E",
"    </strong>",
"    ikenella corrodens; and",
"    <strong>",
"     K",
"    </strong>",
"    ingella kingae) were traditionally thought to be the most common agents of culture-negative endocarditis. However, studies have found that the HACEK organisms can be easily isolated with current blood culture systems when incubated for at least five days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A multicenter, retrospective study at three university medical centers during the time period 2003 to 2004 addressed the ability to culture HACEK bacteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/20\">",
"     20",
"    </a>",
"    ]. Findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean and median times to detection of HACEK isolates from blood cultures were 3.4 and 3 days, respectively.",
"     </li>",
"     <li>",
"      None of 407 blood cultures in patients with suspected culture-negative endocarditis grew HACEK or other bacteria with extended incubation (10 to 14 days).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common causative agents of blood culture-negative IE are fastidious organisms (eg, zoonotic agents and fungi) and Streptococcal spp in patients who have received previous antibiotic treatment.",
"   </p>",
"   <p>",
"    A prospective study of 348 patients with suspected culture-negative endocarditis (by modified Duke criteria) was conducted to identify the etiologic agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/15\">",
"     15",
"    </a>",
"    ]. Studies included serologic tests for Coxiella burnetii, Bartonella spp, Chlamydophila spp, Legionella spp, Aspergillus spp; blood culture on shell vial; and when the valve specimens were available, culture, microscopic examination, and direct PCR amplification.",
"   </p>",
"   <p>",
"    An etiologic agent was identified in 275 patients (79 percent) and included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      C. burnetii in 167 cases (48 percent)",
"     </li>",
"     <li>",
"      Bartonella spp in 99 cases (28 percent)",
"     </li>",
"     <li>",
"      Streptococci in 4 cases",
"     </li>",
"     <li>",
"      Tropheryma whipplei in 2 cases",
"     </li>",
"     <li>",
"      Abiotrophia elegans in 1 case",
"     </li>",
"     <li>",
"      Mycoplasma hominis in 1 case",
"     </li>",
"     <li>",
"      Legionella pneumophila in 1 case",
"     </li>",
"     <li>",
"      Escherichia coli in 1 case",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The local prevalence of infection with pathogens such as C. burnetii and Bartonella spp varies widely in different geographic locations and epidemiologic settings. Thus, the utility of these observations may not be applicable to other geographic areas, as this study was performed in southern France, an area with a very high prevalence of C. burnetii infection.",
"   </p>",
"   <p>",
"    However, C. burnetii is a relatively common cause of IE in other European countries besides France and may cause 3 to 10 percent of IE in these countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/21\">",
"     21",
"    </a>",
"    ]. The incidence of Q fever is estimated at 1 in 1 million inhabitants per year in France, Israel, and Switzerland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/22\">",
"     22",
"    </a>",
"    ]. Q fever is less common in Northern Europe and the United Kingdom. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15255?source=see_link\">",
"     \"Q fever endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bartonella endocarditis is also commonly found as a cause of IE in some countries. The prevalence of Bartonella IE varies in Europe, increasing from North to South. The prevalence of Bartonella IE is reported as less than 1 percent in Northern Europe, 1 percent in England, 3 percent in France and Germany, and &ge;10 percent in Tunisia and Algeria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/8,23\">",
"     8,23",
"    </a>",
"    ]. Most of the cases found in Northern Africa are caused by B. quintana. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31830?source=see_link\">",
"     \"Endocarditis caused by Bartonella\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    T. whipplei may be a more important cause of culture negative IE than previously recognized. In an observational cohort study including 255 patients with evidence of bacterial colonization on explanted valve tissue, T. whipplei was isolated in 6 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/24\">",
"     24",
"    </a>",
"    ]. It was the most commonly isolated pathogen in individuals with culture-negative IE and the fourth most commonly isolated pathogen overall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic tests for culture-negative endocarditis include special culturing techniques (eg, shell vial and lysis centrifugation), molecular techniques (eg, polymerase chain reaction and serologic assays), and histopathology evaluation of valvular tissue when surgical excision is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Explanted valve tissue should be evaluated with histopathological examination as well as polymerase chain reaction (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Polymerase chain reaction'",
"    </a>",
"    below). Histopathology can be useful for pathogen identification of infectious endocarditis as well as noninfectious mimickers including marantic endocarditis, rheumatic endocarditis, myxoma and others.",
"   </p>",
"   <p>",
"    Special tissue staining (Gram's, Giemsa, acid-fast, Warthin-Starry, and Periodic acid Schiff [PAS] stain) may allow a presumptive identification of the etiologic agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, immunohistochemistry with specific polyclonal or monoclonal antibodies can identify specific causative agents including Bartonella spp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/25\">",
"     25",
"    </a>",
"    ], C. burnetii [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/26\">",
"     26",
"    </a>",
"    ], and T. whipplei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autoimmunohistochemistry is a novel method to detect microorganisms that uses the patient's own serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/29\">",
"     29",
"    </a>",
"    ]. The rate of detection is higher than culture and similar to PCR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Molecular techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most data on polymerase chain reaction (PCR) for the diagnosis of culture-negative endocarditis come from its use in the setting of explanted valve tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/15,30-35\">",
"     15,30-35",
"    </a>",
"    ], although the technique may also be useful for diagnosis from serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are broad-range PCR techniques for amplifying 16SrDNA (for bacteria) or 18SrDNA (for fungi), which can then be sequenced for pathogen identification. The most frequently identified bacteria have included streptococci, staphylococci, Bartonella spp, and T. whipplei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/15,30-37\">",
"     15,30-37",
"    </a>",
"    ]. In addition, there are real-time PCR techniques for diagnosis of specific pathogens including Bartonella spp, C. burnetii (Q fever), and Whipple's disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31830?source=see_link\">",
"     \"Endocarditis caused by Bartonella\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15255?source=see_link\">",
"     \"Q fever endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/35/11833?source=see_link\">",
"     \"Whipple's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sensitivity of PCR for pathogen identification in culture-negative endocarditis ranges from 40 to 60 percent, with specificity nearing 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These studies used a gold standard of Duke criteria together with histopathologic examination. In comparison, valve culture rates have a sensitivity of up to 13 percent, and histopathology sensitivity can vary from 12 to 63 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limitations of PCR can lead to false-negative or false-positive results. False negative results can occur in the setting of preoperative antibiotics, which probably decrease the diagnostic yield of valve tissue PCR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/38\">",
"     38",
"    </a>",
"    ]. False positive results may occur in the setting of persistent nonviable bacteria months or years after apparent cure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, PCR can be falsely positive if valve tissue is contaminated in the process of surgical removal or transport (in which case the control would be negative). Thus, a positive PCR test from valve tissue must be correlated with the known propensity of the detected microbe to cause IE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Serologic assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiologic agents in culture-negative IE best identified by serology include Coxiella burnetii, Bartonella spp, Chlamydophila (formerly Chlamydia) spp, Legionella spp, and Brucella spp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/2\">",
"     2",
"    </a>",
"    ]. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Coxiella burnetii phase I antibody titers &gt;800 are diagnostic for Q fever endocarditis, and Bartonella IgG levels &ge;800 are diagnostic for Bartonella spp. IE is diagnosed with [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/2\">",
"     2",
"    </a>",
"    ]. However, patients with Q fever may have low-level cross-reacting antibodies to Bartonella spp",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Chlamydophila spp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/21\">",
"     21",
"    </a>",
"    ]. Furthermore, the role of Chlamydophila spp in the etiology of IE is controversial and difficult to ascertain because of the cross-reacting antibodies to Bartonella spp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Special culture techniques",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Lysis centrifugation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lysis centrifugation can improve yield of fastidious organisms (eg, Brucella spp and fungi) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. This culture system contains components that lyse leukocytes and erythrocytes, as well as inactivate plasma complement and certain antibiotics. The cell lysis allows release of intracellular microorganisms, and the centrifugation step concentrates the organisms which can then be plated directly onto supportive medium. Recovery of skin flora should be interpreted with caution, since lysis centrifugation is more likely to be affected by contamination than routine blood cultures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Shell vial cell culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shell vial cell culture assay of blood or excised heart valves allows the isolation of Coxiella burnetii, Bartonella spp, T. whipplei, and Brucella spp and has been useful in identifying the etiologic agent in culture-negative IE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34646/abstract/42\">",
"     42",
"    </a>",
"    ]. This technique is restricted to specialized laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood culture-negative IE is defined as endocarditis without etiology following inoculation of three independent blood samples in a standard blood culture system with negative cultures after seven days of incubation and subculturing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cultures remain negative in two to seven percent of patients with IE even when the utmost care is taken in obtaining the proper number and volume of blood cultures and patients with prior antibiotic treatment are excluded; the frequency is higher in patients who have already been treated with antibiotics. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cultures are negative in patients with IE for three major reasons:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;- Previous administration of antimicrobial agents",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;- Inadequate microbiological techniques",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;- Infection with highly fastidious bacteria or nonbacterial pathogens (eg, fungi) (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Incidence'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of culture-negative IE varies by country, with a higher proportion of IE being culture-negative in developing countries. The differences in frequency reflect the increased incidence of fastidious zoonotic agents causing human infection in developing countries, the differences in microbiologic techniques, and perhaps, the availability of antibiotics without prescription in some countries. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HACEK organisms can be easily isolated with current blood culture systems when incubated for at least five days and are not a common cause of culture-negative IE. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Possible etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causative agents of blood culture-negative IE are fastidious organisms (eg, zoonotic agents and fungi) and Streptococcal spp in patients who have received previous antibiotic treatment. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Possible etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The local prevalence of infection with pathogens such as C. burnetii and Bartonella spp, the most common agents of culture-negative endocarditis, varies widely in different geographic locations and epidemiologic settings. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Possible etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serology and PCR help on blood samples or removed valves help to identify fastidious pathogens.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/1\">",
"      Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. Clin Microbiol Rev 2001; 14:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/2\">",
"      Raoult D, Casalta JP, Richet H, et al. Contribution of systematic serological testing in diagnosis of infective endocarditis. J Clin Microbiol 2005; 43:5238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/3\">",
"      Molavi A. Endocarditis: recognition, management, and prophylaxis. Cardiovasc Clin 1993; 23:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/4\">",
"      Hoen B, Selton-Suty C, Lacassin F, et al. Infective endocarditis in patients with negative blood cultures: analysis of 88 cases from a one-year nationwide survey in France. Clin Infect Dis 1995; 20:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/5\">",
"      Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001; 345:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/6\">",
"      Werner M, Andersson R, Olaison L, Hogevik H. A clinical study of culture-negative endocarditis. Medicine (Baltimore) 2003; 82:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/7\">",
"      Zamorano J, Sanz J, Almer&iacute;a C, et al. Differences between endocarditis with true negative blood cultures and those with previous antibiotic treatment. J Heart Valve Dis 2003; 12:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/8\">",
"      Benslimani A, Fenollar F, Lepidi H, Raoult D. Bacterial zoonoses and infective endocarditis, Algeria. Emerg Infect Dis 2005; 11:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/9\">",
"      Koegelenberg CF, Doubell AF, Orth H, Reuter H. Infective endocarditis in the Western Cape Province of South Africa: a three-year prospective study. QJM 2003; 96:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/10\">",
"      Tariq M, Alam M, Munir G, et al. Infective endocarditis: a five-year experience at a tertiary care hospital in Pakistan. Int J Infect Dis 2004; 8:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/11\">",
"      Krcmery V, Gogov&aacute; M, Ondrusov&aacute; A, et al. Etiology and risk factors of 339 cases of infective endocarditis: report from a 10-year national prospective survey in the Slovak Republic. J Chemother 2003; 15:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/12\">",
"      Cecchi E, Forno D, Imazio M, et al. New trends in the epidemiological and clinical features of infective endocarditis: results of a multicenter prospective study. Ital Heart J 2004; 5:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/13\">",
"      Lamas CC, Eykyn SJ. Blood culture negative endocarditis: analysis of 63 cases presenting over 25 years. Heart 2003; 89:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/14\">",
"      Nakatani S, Mitsutake K, Hozumi T, et al. Current characteristics of infective endocarditis in Japan: an analysis of 848 cases in 2000 and 2001. Circ J 2003; 67:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/15\">",
"      Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. Medicine (Baltimore) 2005; 84:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/16\">",
"      Roger PM, Boissy C, Gari-Toussaint M, et al. Medical treatment of a pacemaker endocarditis due to Candida albicans and to Candida glabrata. J Infect 2000; 41:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/17\">",
"      Acquati F, Semeraro F, Respighi E, et al. Aspergillus flavus-infection of a pacemaker wire: continuing evidence for active management of infected pacemakers. G Ital Cardiol 1987; 17:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/18\">",
"      Barbone A, Pini D, Grossi P, et al. Aspergillus left ventricular assist device endocarditis. Ital Heart J 2004; 5:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/19\">",
"      Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive subculturing do not increase recovery of clinically significant microorganisms from standard automated blood cultures. Clin Infect Dis 2005; 41:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/20\">",
"      Petti CA, Bhally HS, Weinstein MP, et al. Utility of extended blood culture incubation for isolation of Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, and Kingella organisms: a retrospective multicenter evaluation. J Clin Microbiol 2006; 44:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/21\">",
"      Houpikian P, Raoult D. Diagnostic methods. Current best practices and guidelines for identification of difficult-to-culture pathogens in infective endocarditis. Cardiol Clin 2003; 21:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/22\">",
"      Maurin M, Raoult D. Q fever. Clin Microbiol Rev 1999; 12:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/23\">",
"      Znazen A, Rolain JM, Hammami N, et al. High prevalence of Bartonella quintana endocarditis in Sfax, Tunisia. Am J Trop Med Hyg 2005; 72:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/24\">",
"      Geissd&ouml;rfer W, Moos V, Moter A, et al. High frequency of Tropheryma whipplei in culture-negative endocarditis. J Clin Microbiol 2012; 50:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/25\">",
"      Lepidi H, Fournier PE, Raoult D. Quantitative analysis of valvular lesions during Bartonella endocarditis. Am J Clin Pathol 2000; 114:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/26\">",
"      Lepidi H, Houpikian P, Liang Z, Raoult D. Cardiac valves in patients with Q fever endocarditis: microbiological, molecular, and histologic studies. J Infect Dis 2003; 187:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/27\">",
"      Lepidi H, Fenollar F, Dumler JS, et al. Cardiac valves in patients with Whipple endocarditis: microbiological, molecular, quantitative histologic, and immunohistochemical studies of 5 patients. J Infect Dis 2004; 190:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/28\">",
"      Dumler JS, Baisden BL, Yardley JH, Raoult D. Immunodetection of Tropheryma whipplei in intestinal tissues from Dr. Whipple's 1907 patient. N Engl J Med 2003; 348:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/29\">",
"      Lepidi H, Coulibaly B, Casalta JP, Raoult D. Autoimmunohistochemistry: a new method for the histologic diagnosis of infective endocarditis. J Infect Dis 2006; 193:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/30\">",
"      Breitkopf C, Hammel D, Scheld HH, et al. Impact of a molecular approach to improve the microbiological diagnosis of infective heart valve endocarditis. Circulation 2005; 111:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/31\">",
"      Greub G, Lepidi H, Rovery C, et al. Diagnosis of infectious endocarditis in patients undergoing valve surgery. Am J Med 2005; 118:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/32\">",
"      Bosshard PP, Kronenberg A, Zbinden R, et al. Etiologic diagnosis of infective endocarditis by broad-range polymerase chain reaction: a 3-year experience. Clin Infect Dis 2003; 37:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/33\">",
"      Grijalva M, Horv&aacute;th R, Dendis M, et al. Molecular diagnosis of culture negative infective endocarditis: clinical validation in a group of surgically treated patients. Heart 2003; 89:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/34\">",
"      Gauduchon V, Chalabreysse L, Etienne J, et al. Molecular diagnosis of infective endocarditis by PCR amplification and direct sequencing of DNA from valve tissue. J Clin Microbiol 2003; 41:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/35\">",
"      Podglajen I, Bellery F, Poyart C, et al. Comparative molecular and microbiologic diagnosis of bacterial endocarditis. Emerg Infect Dis 2003; 9:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/36\">",
"      Millar B, Moore J, Mallon P, et al. Molecular diagnosis of infective endocarditis--a new Duke's criterion. Scand J Infect Dis 2001; 33:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/37\">",
"      Rampini SK, Bloemberg GV, Keller PM, et al. Broad-range 16S rRNA gene polymerase chain reaction for diagnosis of culture-negative bacterial infections. Clin Infect Dis 2011; 53:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/38\">",
"      Rice PA, Madico GE. Polymerase chain reaction to diagnose infective endocarditis: will it replace blood cultures? Circulation 2005; 111:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/39\">",
"      Rovery C, Greub G, Lepidi H, et al. PCR detection of bacteria on cardiac valves of patients with treated bacterial endocarditis. J Clin Microbiol 2005; 43:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/40\">",
"      Mantur BG, Mangalgi SS. Evaluation of conventional castaneda and lysis centrifugation blood culture techniques for diagnosis of human brucellosis. J Clin Microbiol 2004; 42:4327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/41\">",
"      Archibald LK, McDonald LC, Addison RM, et al. Comparison of BACTEC MYCO/F LYTIC and WAMPOLE ISOLATOR 10 (lysis-centrifugation) systems for detection of bacteremia, mycobacteremia, and fungemia in a developing country. J Clin Microbiol 2000; 38:2994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34646/abstract/42\">",
"      Gouriet F, Fenollar F, Patrice JY, et al. Use of shell-vial cell culture assay for isolation of bacteria from clinical specimens: 13 years of experience. J Clin Microbiol 2005; 43:4993.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2144 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34646=[""].join("\n");
var outline_f33_53_34646=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Possible etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Molecular techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Serologic assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Special culture techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Lysis centrifugation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Shell vial cell culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/5/31830?source=related_link\">",
"      Endocarditis caused by Bartonella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15255?source=related_link\">",
"      Q fever endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/35/11833?source=related_link\">",
"      Whipple's disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_53_34647="Clinical manifestations and diagnosis of myocarditis in children";
var content_f33_53_34647=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of myocarditis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34647/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34647/contributors\">",
"     Catherine K Allan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34647/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34647/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34647/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34647/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34647/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34647/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/53/34647/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocarditis is a condition resulting from inflammation of the heart muscle. Myocellular damage results in myocardial dysfunction leading to heart failure. The clinical presentation can be acute or chronic. However, in contrast to adults, the majority of children with myocarditis present with acute or fulminant disease.",
"   </p>",
"   <p>",
"    The causes of myocarditis are diverse and include infectious, toxic, and autoimmune etiologies (",
"    <a class=\"graphic graphic_table graphicRef56995 \" href=\"mobipreview.htm?35/10/36014\">",
"     table 1",
"    </a>",
"    ). Infectious etiologies, particularly viral, are most common in children. The most common causes of viral myocarditis are enterovirus (coxsackie group B), adenovirus, parvovirus B19, and human herpes 6 (HHV-6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/1\">",
"     1",
"    </a>",
"    ]; cases may be sporadic or epidemic and have seasonal and geographical variation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence, clinical manifestations, and diagnosis of myocarditis in children are reviewed here. The treatment and prognosis of myocarditis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22986?source=see_link\">",
"     \"Etiology and pathogenesis of myocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2647?source=see_link\">",
"     \"Treatment and prognosis of myocarditis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of myocarditis in children is unknown, in part because affected patients may be asymptomatic and found to have evidence of myocarditis after unexpected death.",
"   </p>",
"   <p>",
"    This is illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory infiltrates and myocardial cell damage were found at autopsy in 3 to 40 percent of infants and children who died suddenly unrelated to trauma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/4-8\">",
"       4-8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Viral RNA was detected in myocardial tissue in 6 of 13 patients ages 2 to 67 years of age who had sudden unexpected death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As many as 17 percent of infants who died of sudden infant death syndrome (SIDS) had histopathologic evidence of myocarditis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. In infants who died of SIDS, adenovirus and enterovirus genomes were detected in some with evidence of myocarditis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/13,14\">",
"       13,14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is difficult to estimate the incidence of the disease because there is no sensitive and specific diagnostic test for myocarditis. As a result, the diagnosis often is not confirmed. In one retrospective study from a single tertiary Canadian center, the estimated prevalence of myocarditis presenting to their emergency department was 0.5 cases per 10,000 visits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/15\">",
"     15",
"    </a>",
"    ]. Other reports suggest an annual incidence of 1 per 100,000 children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Diagnostic studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In another study, a review of all the autopsies performed at a single English pediatric tertiary center over a ten-year period (1996 to 2005) identified 28 of 1516 cases with myocarditis (1.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/17\">",
"     17",
"    </a>",
"    ]. The median age was 10 months (range 10 days to 16 years), and 15 deaths occurred before one year of age. Sixteen cases presented as sudden deaths. Virus was detected in 9 of 25 cases in whom virological analyses were performed.",
"   </p>",
"   <p>",
"    In a large case series using the Pediatric Health Information System (PHIS) database, the following demographic findings were noted in 514 children with a diagnosis of myocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean age of diagnosis was 9.2 years of age. There was a bimodal distribution with peaks of cases in infancy (between 6 and 12 months of age) and adolescence (16 years of age). Overall, males accounted for two-thirds of the patients. In patients less than 12 years of age, there was an equal distribution between males and females and, in adolescent patients, the male to female ratio was 4 to 1.",
"     </li>",
"     <li>",
"      Ethnic distribution: Non-Hispanic white (41 percent), blacks (22 percent), and Hispanics (18 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of myocarditis is variable. Affected patients can present with a broad clinical spectrum of disease that can be acute, fulminant, or chronic. Some patients have a coexistent pericarditis.",
"   </p>",
"   <p>",
"    Patients with viral myocarditis, the most common etiology in children, frequently have a prodrome of fever, myalgia, and malaise several days prior to the onset of heart failure. Those with myocarditis due to autoimmune disorders may have symptoms of systemic disease.",
"   </p>",
"   <p>",
"    Infants and children with acute myocarditis often present with signs and symptoms of heart failure including dyspnea at rest, exercise intolerance, syncope, tachypnea, tachycardia, and hepatomegaly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. However, non-specific signs and symptoms such as respiratory distress or gastrointestinal symptoms may be the most prominent features at presentation, leading to an incorrect initial diagnosis in many children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/15,23\">",
"     15,23",
"    </a>",
"    ]. The emergent evaluation of children and adolescents with respiratory distress is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7130?source=see_link\">",
"     \"Emergent evaluation of acute respiratory compromise in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tachycardia and metabolic acidosis may be important indicators of the extent of myocardial involvement. Supraventricular and ventricular arrhythmias and complete heart block may be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/2,21,24,25\">",
"     2,21,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute myocarditis is distinguished from fulminant myocarditis, which is associated with an acute onset and severe hemodynamic compromise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/26\">",
"     26",
"    </a>",
"    ]. Children with fulminant myocarditis are critically ill [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/2\">",
"     2",
"    </a>",
"    ]. They present with signs of decreased cardiac output, including hypotension, poor pulses, and decreased perfusion, which may progress to cardiovascular collapse. Malignant arrhythmias are common.",
"   </p>",
"   <p>",
"    In some cases, myocarditis may be asymptomatic. It may present with sudden unexpected death that is presumably due to ventricular arrhythmia.",
"   </p>",
"   <p>",
"    Because of the high risk of arrhythmias and hemodynamic compromise, affected patients should be monitored in a pediatric intensive care unit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In symptomatic patients, the physical examination often reveals direct evidence of cardiac dysfunction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs of respiratory distress resulting from left elevated atrial pressures and pulmonary venous congestion include tachypnea and retractions.",
"     </li>",
"     <li>",
"      S3 and occasionally S4 gallops may be present and are important signs of impaired ventricular function, particularly when biventricular acute myocardial involvement results in systemic and pulmonary congestion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link\">",
"       \"Auscultation of heart sounds\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the right or left ventricular dilation is severe, auscultation may reveal murmurs of functional mitral or tricuspid insufficiency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In acute fulminant myocarditis, signs of low cardiac output may be present, including hypotension, poor pulses and perfusion, and altered mental status.",
"     </li>",
"     <li>",
"      A pericardial friction rub and effusion may become evident in some patients with myopericarditis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of the child with suspected myocarditis includes chest radiograph, electrocardiogram (ECG), and cardiac enzymes. An echocardiogram should be performed to evaluate ventricular function and the degree of mitral regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/22\">",
"     22",
"    </a>",
"    ], and to rule out alternative diagnoses such as anomalous left coronary artery from the pulmonary artery (ALCAPA).",
"   </p>",
"   <p>",
"    Endomyocardial biopsy is considered the gold standard for the diagnosis of myocarditis; however, the sensitivity of this test is low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographic findings typically include cardiomegaly, although heart size may be normal. Pulmonary vascular congestion is often present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG in myocarditis may be normal or abnormal. The abnormalities are nonspecific and include low voltages and inverted T waves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/19-21,27\">",
"     19-21,27",
"    </a>",
"    ]. The rhythm is most commonly sinus tachycardia. However, ventricular premature beats, atrial premature beats, supraventricular tachycardia, and ventricular tachycardia may be seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Complete heart block occurs less often [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/2,21,24,25\">",
"     2,21,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiac enzymes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac enzyme elevations reflect myocardial necrosis. They are seen in some, but not all, pediatric patients with myocarditis. In particular, cardiac tropin levels are generally elevated in children with myocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/30\">",
"     30",
"    </a>",
"    ]. Experimental and clinical findings in adults suggest that elevations of cardiac troponin I or T (cTnI or cTnT) levels may be more common than CK-MB elevations in patients with biopsy-proven myocarditis (34 versus 6 percent and 53 versus 2 percent in two reports) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The elevations of cTnI were correlated with a short duration (less than one month) of heart failure symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/31\">",
"     31",
"    </a>",
"    ], suggesting that the majority of myocardial necrosis occurs early in the course of the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac troponin T and CK-MB may be helpful in distinguishing acute myocarditis from chronic dilated cardiomyopathy. In a study in children with acute heart failure and myocardial dysfunction, troponin T and CK-MB levels were higher in myocarditis compared to dilated cardiomyopathy, reflecting ongoing myocellular damage in the former [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Echocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echocardiogram typically shows left ventricular dysfunction. Morphologic findings may distinguish acute from fulminant myocarditis. In one study, left ventricular diastolic dimensions were increased in acute and near normal in fulminant disease, while septal thickness was normal in acute and increased in fulminant disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/26\">",
"     26",
"    </a>",
"    ]. Doppler studies often show mitral regurgitation. Patients who also have pericarditis typically have a pericardial effusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging with contrast can document the location and extent of inflammation. In three studies of adult patients, gadolinium enhancement was greater in patients with myocarditis than in normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Areas of enhancement were focal in the first one to two weeks following onset of symptoms and became more generalized later in the course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. There are no studies specifically addressing sensitivity and specificity of cardiac MRI to diagnose myocarditis in pediatric patients, but this testing modality is increasingly utilized in the pediatric population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional laboratory testing should be guided by the clinical presentation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The erythrocyte sedimentation rate is frequently elevated in myocarditis, but is nonspecific and not useful in establishing a diagnosis.",
"     </li>",
"     <li>",
"      A complete blood count may show evidence of infection.",
"     </li>",
"     <li>",
"      Blood gases may demonstrate a metabolic acidosis in children with acute fulminant myocarditis. Although respiratory distress is typically present, these patients usually have a low arterial PCO2, indicating respiratory compensation.",
"     </li>",
"     <li>",
"      Viral cultures and titers ��� Viral infection should be suspected in patients with acute onset of symptoms, especially those with a prodrome of fever, myalgias, and malaise. Swabs from rectal and nasal mucosa should be cultured for viruses. In the absence of positive viral cultures, acute and convalescent antibody titers can be helpful in the diagnosis of a specific viral infection. If an endomyocardial biopsy is performed, samples should be sent for viral and bacterial culture and, if available, PCR analysis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Endomyocardial biopsy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      A thorough history and physical examination may suggest less frequent infections etiologies such as Lyme carditis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/37\">",
"       37",
"      </a>",
"      ] and diagnostic testing should be adjusted appropriately.",
"     </li>",
"     <li>",
"      Noninfectious causes should be considered in patients who have signs and symptoms of associated systemic disease. Additional testing for connective tissue disease or other disorders may be appropriate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac catheterization typically reveals depressed cardiac index, elevated left ventricular end diastolic pressure, and elevated mean atrial pressure. Angiography shows decreased left ventricular function with or without mitral regurgitation. The main purpose of catheterization is to obtain samples by endomyocardial biopsy (EMB) for pathologic and microbiologic analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Endomyocardial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endomyocardial biopsy (EMB) is considered the gold standard for the diagnosis of myocarditis. The histopathologic diagnosis is made according to the Dallas criteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dallas criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Dallas criteria were developed by a panel of cardiac pathologists in 1986 to establish standard histopathologic criteria for myocarditis. These criteria are used by most investigators to define the disease as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Active myocarditis is defined as \"an inflammatory infiltrate of the myocardium with necrosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      degeneration of adjacent myocytes not typical of the ischemic damage associated with coronary heart disease\". The infiltrates usually are mononuclear, but may be neutrophilic or, occasionally, eosinophilic (",
"      <a class=\"graphic graphic_picture graphicRef67761 graphicRef66465 \" href=\"mobipreview.htm?41/4/42058\">",
"       picture 1A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Borderline myocarditis is the term used if lymphocytic infiltration is present without myocyte destruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;However, the sensitivity of EMB is low and myocarditis is confirmed on biopsy in only 20 to 50 percent of pediatric patients and fewer adults with clinically suspected disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. As an example, among 76 biopsies in 63 children with suspected myocarditis, only eight had inflammatory cell infiltrates and myocyte necrosis consistent with the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/39\">",
"     39",
"    </a>",
"    ]. These patients all had duration of symptoms less than six weeks. All four patients who presented with cardiogenic shock had positive biopsies. In another study, only 20 of 39 children (51 percent) with presumed myocarditis met the Dallas criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of sensitivity of EMB is in part related to sampling error. As a result, increasing the number of biopsy specimens obtained increases the sensitivity of the test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/42\">",
"     42",
"    </a>",
"    ]. The duration of symptoms at the time the biopsy is performed also may influence the likelihood of a confirmed tissue diagnosis. A positive result is more likely if the biopsy is performed soon after the onset of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, although the Dallas criteria are widely used, their interpretation remains somewhat subjective. Although a histologically normal EMB does not exclude myocarditis, findings of chronic changes such as fibrosis may help differentiate myocarditis from cardiomyopathy, which has important prognostic implications.",
"   </p>",
"   <p>",
"    The use of more specific testing in addition to standard light microscopy may improve the sensitivity and specificity of EMB. As an example, immunocytochemistry using monoclonal antibodies against white blood cell subsets has been used experimentally to differentiate myocarditis and cardiomyopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/43\">",
"     43",
"    </a>",
"    ]. Viral culture of biopsy specimens may identify an etiology of myocarditis, but positive cultures are rare and obtained only early in the course of the disease. Perhaps the most helpful approach is the use of molecular techniques such as in situ hybridization and PCR amplification of viral DNA. In one study, viral genome was detected in 239 of 624 specimens (38 percent) of adults and children with suspected myocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/44\">",
"     44",
"    </a>",
"    ]. Adenovirus and enterovirus were the most common viral genomes detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of complications of EMB in children was approximately 1 percent in two large series in which the procedure was performed for suspected myocarditis or surveillance for heart transplant rejection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In one study, perforation of the right ventricle was the most frequent complication and most likely to occur in patients who were being evaluated for myocarditis, required inotropic support, or weighed less than 10 kg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/45\">",
"     45",
"    </a>",
"    ]. Other complications included arrhythmias, pneumothorax, and flail tricuspid leaflet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Society statements",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Heart Association (AHA), the American College of Cardiology (ACC), and the European Society of Cardiology (ESC) released a scientific statement on the role of EMB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/47\">",
"     47",
"    </a>",
"    ]. Although the statement noted that limited data are available on EMB in children, the statement concluded based upon expert opinion that EMB is reasonable in the setting of unexplained cardiomyopathy in children. Indications include fulminant or acute unexplained heart failure, cardiac transplant rejection monitoring, certain unexplained arrhythmias, and idiopathic dilated cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=see_link&amp;anchor=H12#H12\">",
"     \"Endomyocardial biopsy\", section on 'Unexplained cardiomyopathy in children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform EMB on the majority of patients with new symptoms of heart failure unrelated to structural heart disease because it may provide important diagnostic and prognostic information and can usually be performed safely. Although we recognize the low yield with routine histologic examination, evidence of myocarditis is associated with a good chance of recovery of myocardial function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/39,48,49\">",
"     39,48,49",
"    </a>",
"    ]. In the report cited above of 63 children evaluated for possible myocarditis, five of eight patients with a positive biopsy had complete clinical resolution while only 3 of 33 without myocarditis recovered ventricular function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34647/abstract/39\">",
"     39",
"    </a>",
"    ]. Biopsy may detect other causes of dilated cardiomyopathy, such as storage disease and muscular dystrophy. In some cases, EMB may identify a specific infectious etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/56/11138?source=see_link\">",
"       \"Patient information: Pericarditis in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myocarditis should be suspected in a child with the acute onset of heart failure and no structural heart disease, especially after a viral prodrome. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation should include a chest radiograph, electrocardiogram, and cardiac enzymes. An echocardiogram should be performed to exclude structural heart disease and assess ventricular function. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnostic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An endomyocardial biopsy should be performed because it may provide important diagnostic and prognostic information and can usually be performed safely. In addition to histopathology, viral cultures and molecular techniques should be used to identify an infectious etiology. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Endomyocardial biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the high risk of arrhythmias and hemodynamic compromise, affected patients should be monitored in a pediatric intensive care unit.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/1\">",
"      Tsch&ouml;pe C, Bock CT, Kasner M, et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/2\">",
"      Mounts AW, Amr S, Jamshidi R, et al. A cluster of fulminant myocarditis cases in children, Baltimore, Maryland, 1997. Pediatr Cardiol 2001; 22:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/3\">",
"      Strikas RA, Anderson LJ, Parker RA. Temporal and geographic patterns of isolates of nonpolio enterovirus in the United States, 1970-1983. J Infect Dis 1986; 153:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/4\">",
"      Forcada P, Beigelman R, Milei J. Inapparent myocarditis and sudden death in pediatrics. Diagnosis by immunohistochemical staining. Int J Cardiol 1996; 56:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/5\">",
"      Maron BJ, Gohman TE, Aeppli D. Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes. J Am Coll Cardiol 1998; 32:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/6\">",
"      Neuspiel DR, Kuller LH. Sudden and unexpected natural death in childhood and adolescence. JAMA 1985; 254:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/7\">",
"      Topaz O, Edwards JE. Pathologic features of sudden death in children, adolescents, and young adults. Chest 1985; 87:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/8\">",
"      Niimura I, Maki T. Sudden cardiac death in childhood. Jpn Circ J 1989; 53:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/9\">",
"      Cioc AM, Nuovo GJ. Histologic and in situ viral findings in the myocardium in cases of sudden, unexpected death. Mod Pathol 2002; 15:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/10\">",
"      Rajs J, Hammarquist F. Sudden infant death in Stockholm. A forensic pathology study covering ten years. Acta Paediatr Scand 1988; 77:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/11\">",
"      deSa DJ. Isolated myocarditis as a cause of sudden death in the first year of life. Forensic Sci Int 1986; 30:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/12\">",
"      R&aring;sten-Almqvist P, Eksborg S, Rajs J. Myocarditis and sudden infant death syndrome. APMIS 2002; 110:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/13\">",
"      Shimizu C, Rambaud C, Cheron G, et al. Molecular identification of viruses in sudden infant death associated with myocarditis and pericarditis. Pediatr Infect Dis J 1995; 14:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/14\">",
"      Dettmeyer R, Baasner A, Schlamann M, et al. Coxsackie B3 myocarditis in 4 cases of suspected sudden infant death syndrome: diagnosis by immunohistochemical and molecular-pathologic investigations. Pathol Res Pract 2002; 198:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/15\">",
"      Freedman SB, Haladyn JK, Floh A, et al. Pediatric myocarditis: emergency department clinical findings and diagnostic evaluation. Pediatrics 2007; 120:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/16\">",
"      Levine MC, Klugman D, Teach SJ. Update on myocarditis in children. Curr Opin Pediatr 2010; 22:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/17\">",
"      Weber MA, Ashworth MT, Risdon RA, et al. Clinicopathological features of paediatric deaths due to myocarditis: an autopsy series. Arch Dis Child 2008; 93:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/18\">",
"      Ghelani SJ, Spaeder MC, Pastor W, et al. Demographics, trends, and outcomes in pediatric acute myocarditis in the United States, 2006 to 2011. Circ Cardiovasc Qual Outcomes 2012; 5:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/19\">",
"      Bonadio WA, Losek JD. Infants with myocarditis presenting with severe respiratory distress and shock. Pediatr Emerg Care 1987; 3:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/20\">",
"      Press S, Lipkind RS. Acute myocarditis in infants. Initial presentation. Clin Pediatr (Phila) 1990; 29:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/21\">",
"      Greenwood RD, Nadas AS, Fyler DC. The clinical course of primary myocardial disease in infants and children. Am Heart J 1976; 92:549.",
"     </a>",
"    </li>",
"    <li>",
"     Towbin, JA. Cardiomyopathies. In: Pediatric Cardiovascular Medicine, Moller, JH (Ed), Churchill Livingstone, 2000. p.758.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/23\">",
"      Durani Y, Egan M, Baffa J, et al. Pediatric myocarditis: presenting clinical characteristics. Am J Emerg Med 2009; 27:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/24\">",
"      Wang JN, Tsai YC, Lee WL, et al. Complete atrioventricular block following myocarditis in children. Pediatr Cardiol 2002; 23:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/25\">",
"      Batra AS, Epstein D, Silka MJ. The clinical course of acquired complete heart block in children with acute myocarditis. Pediatr Cardiol 2003; 24:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/26\">",
"      Felker GM, Boehmer JP, Hruban RH, et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 2000; 36:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/27\">",
"      Snyder M. Pediatric viral myocarditis. Air Med J 2003; 22:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/28\">",
"      Friedman RA, Kearney DL, Moak JP, et al. Persistence of ventricular arrhythmia after resolution of occult myocarditis in children and young adults. J Am Coll Cardiol 1994; 24:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/29\">",
"      Balaji S, Wiles HB, Sens MA, Gillette PC. Immunosuppressive treatment for myocarditis and borderline myocarditis in children with ventricular ectopic rhythm. Br Heart J 1994; 72:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/30\">",
"      Eisenberg MA, Green-Hopkins I, Alexander ME, Chiang VW. Cardiac troponin T as a screening test for myocarditis in children. Pediatr Emerg Care 2012; 28:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/31\">",
"      Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation 1997; 95:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/32\">",
"      Lauer B, Niederau C, K&uuml;hl U, et al. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 1997; 30:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/33\">",
"      Soongswang J, Durongpisitkul K, Ratanarapee S, et al. Cardiac troponin T: its role in the diagnosis of clinically suspected acute myocarditis and chronic dilated cardiomyopathy in children. Pediatr Cardiol 2002; 23:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/34\">",
"      Friedrich MG, Strohm O, Schulz-Menger J, et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 1998; 97:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/35\">",
"      Laissy JP, Messin B, Varenne O, et al. MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest 2002; 122:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/36\">",
"      Roditi GH, Hartnell GG, Cohen MC. MRI changes in myocarditis--evaluation with spin echo, cine MR angiography and contrast enhanced spin echo imaging. Clin Radiol 2000; 55:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/37\">",
"      Costello JM, Alexander ME, Greco KM, et al. Lyme carditis in children: presentation, predictive factors, and clinical course. Pediatrics 2009; 123:e835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/38\">",
"      Aretz HT, Billingham ME, Edwards WD, et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987; 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/39\">",
"      Webber SA, Boyle GJ, Jaffe R, et al. Role of right ventricular endomyocardial biopsy in infants and children with suspected or possible myocarditis. Br Heart J 1994; 72:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/40\">",
"      Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/41\">",
"      Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/42\">",
"      Chow LH, Radio SJ, Sears TD, McManus BM. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 1989; 14:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/43\">",
"      Cassling RS, Linder J, Sears TD, et al. Quantitative evaluation of inflammation in biopsy specimens from idiopathically failing or irritable hearts: experience in 80 pediatric and adult patients. Am Heart J 1985; 110:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/44\">",
"      Bowles NE, Ni J, Kearney DL, et al. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003; 42:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/45\">",
"      Pophal SG, Sigfusson G, Booth KL, et al. Complications of endomyocardial biopsy in children. J Am Coll Cardiol 1999; 34:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/46\">",
"      Cowley CG, Lozier JS, Orsmond GS, Shaddy RE. Safety of endomyocardial biopsy in children. Cardiol Young 2003; 13:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/47\">",
"      Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 2007; 116:2216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/48\">",
"      Gagliardi MG, Bevilacqua M, Squitieri C, et al. Dilated cardiomyopathy caused by acute myocarditis in pediatric patients: evolution of myocardial damage in a group of potential heart transplant candidates. J Heart Lung Transplant 1993; 12:S224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34647/abstract/49\">",
"      Fenoglio JJ Jr, Ursell PC, Kellogg CF, et al. Diagnosis and classification of myocarditis by endomyocardial biopsy. N Engl J Med 1983; 308:12.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5755 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34647=[""].join("\n");
var outline_f33_53_34647=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSTIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiac enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dallas criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Society statements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5755\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5755|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/58/36777\" title=\"picture 1A\">",
"      Variola myocarditis Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/58/30633\" title=\"picture 1B\">",
"      Acute diffuse myocarditis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5755|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/10/36014\" title=\"table 1\">",
"      Causes of myocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7130?source=related_link\">",
"      Emergent evaluation of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/56/11138?source=related_link\">",
"      Patient information: Pericarditis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/37/2647?source=related_link\">",
"      Treatment and prognosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_53_34648="Role of mucoactive agents in the treatment of COPD";
var content_f33_53_34648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Role of mucoactive agents in the treatment of COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34648/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34648/contributors\">",
"     Loutfi Sami Aboussouan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34648/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34648/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34648/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34648/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/53/34648/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tracheobronchial mucus contributes significantly to the symptoms of chronic obstructive pulmonary disease (COPD). It is a diagnostic criterion for chronic bronchitis and one of the primary causes of airflow obstruction in asthma. In addition, chronic mucus hypersecretion is associated with increased mortality, an accelerated decline of FEV1, and an increased risk of hospitalization in COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A mucoactive drug is defined as an agent with the capability of modifying mucus production, secretion, its nature and composition, or its interactions with the mucociliary epithelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/4\">",
"     4",
"    </a>",
"    ]. Examples of mucoactive drugs include expectorants (induce cough or increase the volume of secretions), mucolytics (reduce the viscosity of mucus), mucokinetic drugs (increase the mobility and transportability of mucus), and mucoregulators (control the process of hypersecretion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/5\">",
"     5",
"    </a>",
"    ]. Most of the common mucoactive drugs are mucolytics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review suggests that mucoactive drugs help reduce exacerbations of COPD and disability from COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/7\">",
"     7",
"    </a>",
"    ]. However, published standards do not recommend the routine use of these drugs in the management of COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of mucoactive therapy in the management of COPD will be reviewed here. The role of mucoactive agents in the treatment of cystic fibrosis (CF) lung disease and non-CF bronchiectasis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROPERTIES OF MUCUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surface liquid covering the epithelial lining of the airways comprises at least two layers: the mucus layer, and the periciliary watery layer surrounding the cilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/9\">",
"     9",
"    </a>",
"    ]. Mucus consists of a mixture of transudative fluid and secretions from surface epithelium and submucosal glands. It is predominantly composed of water (95 percent) and glycoproteins (2 to 3 percent), with smaller components of proteoglycans (0.1-0.5 percent), lipids (0.3-0.5 percent), proteins, and DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal volume of mucus secretion is approximately 15",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/6\">",
"     6",
"    </a>",
"    ]. Mucus secretion can increase threefold in COPD and 10-fold in cystic fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/9\">",
"     9",
"    </a>",
"    ]. The composition also can change in disease states. As an example, DNA can contribute up to 10 percent of the dry weight of mucus secretions in cystic fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tracheobronchial mucus behaves as a non-Newtonian fluid with viscoelastic properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/6\">",
"     6",
"    </a>",
"    ]. The liquid-like, viscous properties allow the mucus to be extruded by glands, whereas the solid-like, elastic properties permit the transfer, storage, and conversion into motion of the energy imparted by the moving cilia. Glycoproteins are essential for this elasticity of mucus. A surfactant layer between the mucus gel and periciliary fluid (the \"sol\") acts as a lubricant that also facilitates the transfer of energy from beating cilia to mucus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In determining the ability of an agent to promote clearance of secretions, both mucociliary clearance and cough clearance need to be addressed. Different rheologic properties have been reported to have different and potentially antagonistic effects on these two mechanisms of mucus transport. As an example, mucus clearance requires effective transfer of the kinetic energy from beating cilia to the mucus. In that regard, factors that improve mucociliary transport include: a higher mucus elasticity (to store the transmitted energy), lower mucus viscosity (to reduce loss of energy), higher adhesivity (that hinders wave formation in the gel layer), increased spinnability (a measure of the thread forming ability of mucus), increased ciliary beat frequency, a thinner mucus layer, and a periciliary (sol) layer that is just less than the height of the cilia (to improve coupling with ciliary tips) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/5,13,14\">",
"     5,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, factors that improve cough clearance include: a higher mucus viscosity, lower mucus elasticity (to reduce recoil of cough-sheared mucus), lower adhesivity (to promote wave formation in the gel), lower spinnability, a thicker mucous layer, and a periciliary layer that is higher that the height of the cilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/5,15\">",
"     5,15",
"    </a>",
"    ]. However, these general concepts may not always apply across disease states. For instance, in one study of mucus transport in patients with cystic fibrosis, elastic modulus was found to be negatively correlated with mucociliary transport, whereas contact angle (a reflection of surface tension associated with the adhesive properties of mucus: a higher contact angle reflect poor wettability and poor adhesiveness) was negatively correlated with cough clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disease states may affect the rheological properties of mucus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/17\">",
"     17",
"    </a>",
"    ]. For instance, the levels of the gel-forming mucins, MUC5AC and MUC5B, are elevated in the airways and sputum of individuals with chronic respiratory diseases, and may contribute to the viscoelastic properties of mucus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/10\">",
"     10",
"    </a>",
"    ]. Increased purulence of sputum results in increased viscosity, surface tension, elastic modulus, contact angle, and in decreased cough transport, but these effects may be secondary to decreased water content [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients with asthma appear to have the highest sputum viscosity, while patients with cystic fibrosis have lower viscosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with chronic bronchitis and bronchiectasis have sputum with intermediate viscosities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent attention has focused upon the role of the periciliary layer. Studies have shown that transport of the periciliary layer is mucus dependent. This suggests that new therapies for the treatment of cystic fibrosis should focus on the restoration of airway surface liquid volume rather than alteration of its tonicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/9,18\">",
"     9,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MUCOACTIVE STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many modalities ranging from simple hydration to the use of bronchodilators and enzyme solutions have been utilized to alter the characteristics of mucus with varying clinical efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although patients with COPD are often encouraged to drink fluids in order to facilitate sputum production, there is no evidence that this modality is effective. One study, for example, evaluated the effect of hydration on mucus volume, viscoelastic properties of sputum, respiratory symptoms, and forced expiratory volume in one second (FEV1): there were no differences when patients were dehydrated or were treated with hydration (1800 to 2400",
"    <span class=\"nowrap\">",
"     mL/day)",
"    </span>",
"    or ad lib fluid intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Aerosols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertonic saline aerosols have traditionally been used to induce expectoration of sputum for diagnostic evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/20\">",
"     20",
"    </a>",
"    ]. The effects of hypertonic saline that aid the clearance of sputum include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stimulation of a productive cough",
"     </li>",
"     <li>",
"      Decreased sputum spinnability",
"     </li>",
"     <li>",
"      Decreased sputum viscoelasticity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although hypertonic saline has been shown to be beneficial in the treatment of cystic fibrosis, there is no evidence of any therapeutic value of hypertonic saline in COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. In addition, the administration of either isotonic or hypertonic aerosols can induce a significant decrease in lung function in patients with COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/27\">",
"     27",
"    </a>",
"    ]. This deleterious effect may be mast cell-mediated, since the decrease in lung function was most pronounced in patients with increased histamine in their sputum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link&amp;anchor=H6#H6\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\", section on 'Inhaled hypertonic saline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one in vitro study,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    was found to reduce viscoelasticity and spinnability, and improve predicted mucociliary and cough clearance, raising the possibility of aerosol delivery of dextran solution as an additional therapeutic option for mucus retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oral expectorants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral expectorants stimulate the gastric nerve and promote a vagally-mediated increase in airway secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/6\">",
"     6",
"    </a>",
"    ]. As a corollary, all of these agents are actually emetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/26\">",
"     26",
"    </a>",
"    ]. Examples include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16101?source=see_link\">",
"     guaifenesin",
"    </a>",
"    , bromhexine, ipecac, and ammonium salts. Other mechanisms of action may include a reduction in mucus viscosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/6\">",
"     6",
"    </a>",
"    ] or an enhancement of the mucociliary elevator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these actions, there is little evidence that oral expectorants improve lung function or subjective well-being in COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/6,21\">",
"     6,21",
"    </a>",
"    ]. In one study, for example, both bromhexine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16101?source=see_link\">",
"     guaifenesin",
"    </a>",
"    improved tracheobronchial clearance but did not change lung function, the frequency of cough, emotional well-being, or the weight and content of sputum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/21\">",
"     21",
"    </a>",
"    ]. However, in an older report, bromhexine has been shown to reduce viscosity of mucus, increase mucus output, and improve spirometric indices in patients with moderate airway obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Iodide preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iodide acts as a mucolytic by decreasing the viscosity of mucus, facilitating the breakdown of proteins by proteolytic enzymes, and increasing ciliary beat frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/30\">",
"     30",
"    </a>",
"    ]. The iodine preparations are saturated solution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    (SSKI), domiodol, and iodopropylidene glycerol.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SSKI may be effective, but its use may be limited by side effects such as a metallic taste, rash, hyperkalemia (in patients with renal insufficiency), and hypothyroidism, particularly if use is prolonged for more than six weeks. The usual dose is 0.3 to 0.6 mL in a glassful of liquid, four times a day. Its clinical usefulness is uncertain.",
"     </li>",
"     <li>",
"      Domiodol is an organic iodinated mucolytic agent. When administered to tracheostomized patients after laryngectomy, this agent improved cough intensity, sputum quantity and quality, as well as ease of expectoration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iodopropylidene glycerol has been shown to enhance tracheobronchial clearance and mucociliary transport in expectorating patients with chronic bronchitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/30\">",
"       30",
"      </a>",
"      ]. In addition, a randomized, double-blind placebo-controlled study documented improvements in cough, ease of expectoration, and well-being, and a decreased duration of exacerbations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/32\">",
"       32",
"      </a>",
"      ]. However, in a subsequent randomized, double-blind, placebo-controlled, cross-over study, the use of iodinated glycerol for 16 weeks did not improve pulmonary function, well being, or sputum viscoelasticity or clearability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/33\">",
"       33",
"      </a>",
"      ]. This drug is no longer available in the United States after concerns were raised about carcinogenesis in selected strains of rats and mice. The usual dose is 60 mg four times a day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sodium cromoglycate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium cromoglycate can improve the depressed tracheal mucus velocity in asthmatics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/34\">",
"     34",
"    </a>",
"    ]. However, the clinical significance of this finding is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bronchodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchodilators act as mucokinetic agents by improving airflow and facilitating mucus clearance. The different types of bronchodilators also have more specific effects that may be either beneficial or detrimental:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aerosolized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    (a potent sympathomimetic amine with almost exclusive &szlig;-adrenergic activity) has been shown to increase mucus clearance, presumably from increased ciliary beat rate. This effect is not due to bronchial vasodilation, the presence of aqueous aerosol droplets, reflex parasympathetic activation, or bronchodilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Anticholinergics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     Atropine",
"    </a>",
"    is an effective antisialagogue that results in significant reductions in tracheal mucus velocity and mucociliary transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, it has no effect on mucus secretory rate, and the resultant buildup of secretions in the lower airways of susceptible patients with COPD may predispose to bacterial colonization and infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/37/33360?source=see_link\">",
"     Ipratropium",
"    </a>",
"    bromide does not appear to have the same effects as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    . As an example, studies in humans have not detected changes in the clearance of secretions or in sputum volume or viscosity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/39\">",
"     39",
"    </a>",
"    ], while animal studies have shown only minimal depression of ciliary beat frequency and tracheal mucus velocity, with no effect on volume or viscoelastic properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/37\">",
"     37",
"    </a>",
"    ]. Thus, ipratropium bromide can improve airway obstruction without negatively affecting mucociliary clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Aminophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    has been shown to significantly increase tracheobronchial mucociliary clearance in patients with COPD. This improvement occurred without concomitant identifiable improvement in pulmonary function or a change in cough [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/40\">",
"     40",
"    </a>",
"    ]. Potential modes of action include enhanced frequency of ciliary activity and increased discharge from submucosal glands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids can act as a mucoregulator by affecting the underlying cause of mucus hypersecretion. Aerosolized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    at doses in excess of 800",
"    <span class=\"nowrap\">",
"     mcg/day",
"    </span>",
"    has been shown to produce a significant improvement in spirometry in patients with chronic bronchitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/41\">",
"     41",
"    </a>",
"    ]. The benefit appears to result from control of airway inflammation since beclomethasone does not affect mucociliary clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Thiols and thiol derivatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents that sever disulfide bridges (eg, N-acetyl-L-cysteine (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    ), S-carboxymethyl cysteine (carbocisteine), 2-mercaptoethane sulfonate) act directly on mucoproteins, thereby liquefying mucus and lowering its viscosity and may have other potentially relevant antioxidant, anti-inflammatory, and antibacterial properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/6,21\">",
"     6,21",
"    </a>",
"    ]. These drugs are not approved as mucokinetic agents in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     Acetylcysteine",
"    </a>",
"    liquefies mucus and DNA; liquefaction occurs within one minute after inhalation and is maximal at five to ten minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/43\">",
"     43",
"    </a>",
"    ]. When delivered in a nebulized form, it can cause bronchospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/44\">",
"     44",
"    </a>",
"    ], and it is therefore usually given in combination with a beta-adrenergic agonist. This combination may obscure the determination of the independent effects of acetylcysteine on mucociliary clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/45\">",
"     45",
"    </a>",
"    ]. For this reason, most trials have studied oral preparations of acetylcysteine in the chronic management of COPD.",
"   </p>",
"   <p>",
"    Several studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    suggested a small benefit associated with treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. However, these findings have not been universal with some studies suggesting that oral acetylcysteine does not decrease the number of days receiving antibiotics, decrease days in bed, improve sputum volume, or improve mucociliary clearance, compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. This may be a consequence of its poor penetration into bronchoalveolar fluid when administered orally.",
"   </p>",
"   <p>",
"    The largest prospective study of this approach, the multicenter European BRONCUS trial, randomly assigned 523 patients with COPD to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    or placebo for three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/51\">",
"     51",
"    </a>",
"    ]. The number of exacerbations and the change in lung function did not differ between groups, although a subgroup analysis indicated a reduction in exacerbations among patients who were not receiving inhaled glucocorticoids.",
"   </p>",
"   <p>",
"    Routine long-term use of oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    is not recommended because of the minimal potential therapeutic benefit, the inconvenience of therapy, the cost, and potential side effects. However, newer drugs, such as nacystelyn (a lysine salt of N-acetylcysteine with antioxidant properties) may be of research interest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Erdosteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erdosteine is another thiol agent with an established safety profile and generally fewer side gastrointestinal side effects than other thiol derivatives. The EQUALIFE study is a randomized, double-blind trial of 155 patients that demonstrated that compared to placebo, treated patients had a 30 percent reduction in exacerbations, a 58 percent reduction in hospital days, improved health status, and lower COPD-related diseases costs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     S-carboxymethyl cysteine (carbocisteine)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Chinese PEACE study, 709 patients with moderate-to-severe COPD were randomized in a double-blind, trial to receive 500 mg carbocisteine or placebo, 3 times a day for 12 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/57\">",
"     57",
"    </a>",
"    ]. Compared to placebo, patients on carbocisteine had a 0.34 mean reduction of exacerbations per patient per year (1.35 versus 1.01 respectively). Quality of life as measured by the St. George's Respiratory Questionnaire was also significantly improved at 12 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Role of concomitant inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the use of mucolytic thiol derivatives confers additional benefits in patients already on inhaled glucocorticoids (ICS) remains to be determined. For example, the reduction of COPD exacerbations with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    in the BRONCUS trial was confined to the subgroup of patients who were not ICS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/51\">",
"     51",
"    </a>",
"    ]. On the other hand, the Chinese PEACE study did not show a significant interaction on reduction of exacerbations between concomitant use of ICS and carbocisteine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/57\">",
"     57",
"    </a>",
"    ]. However, only 17 percent in the PEACE study received ICS, compared to 70 percent of those in the BRONCUS trial. Further studies are needed to resolve this question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recombinant human DNase",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA released by leukocytes is thought to contribute significantly to the viscosity of mucus in patients with cystic fibrosis (CF). Recombinant human",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"     DNase",
"    </a>",
"    can therefore be considered a mucokinetic agent that may produce improvement in pulmonary function in patients with clinically stable CF. In contrast, recombinant human DNase does not appear to be effective in the management of non-CF bronchiectasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=see_link\">",
"     \"Treatment of bronchiectasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Surfactant",
"    </span>",
"    &nbsp;&mdash;&nbsp;A surfactant layer is present between layers of mucus gel and periciliary fluid, serving effectively to separate these two layers and to facilitate mucus spreading. The lubricant properties of surfactant also promote the transfer of energy from beating cilia to mucus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several observations suggest a potential role for surfactant as a mucoactive substance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decrease in surface-active phospholipid fractions in the sputum of patients with CF (compared to sputum from patients with COPD) has been found to correlate with increased mucus stasis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tracheal instillation of surfactant in anesthetized dogs significantly increases ciliary beat frequency compared to instillation of normal saline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One randomized, double-blind study of 66 patients with stable chronic bronchitis compared the effectiveness of two weeks of thrice daily, nebulized phosphatidylcholine surfactant (Exosurf) versus placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/60\">",
"       60",
"      </a>",
"      ]. The treatment group had increased in vitro sputum transportability, improvement in pre- and postbronchodilator FEV1 and FVC by &gt;10 percent, and mildly decreased",
"      <span class=\"nowrap\">",
"       RV/TLC",
"      </span>",
"      ratios. The high cost of exogenous surfactant precludes its routine use in patients with chronic bronchitis until its salutary effects are better defined in larger trials.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Actin-severing agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gelsolin is an actin-severing agent that has been shown in vitro to reduce the viscosity of sputum samples from patients with CF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/61\">",
"     61",
"    </a>",
"    ]. This effect presumably reflects the presence of filamentous actin in CF sputum. The clinical applicability and effectiveness of gelsolin remain to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are some settings in which increased mucus production should be controlled by antibiotics. Examples include flares of bronchiectasis and purulent exacerbations of chronic bronchitis. There is also some evidence that macrolide antibiotics may inhibit mucus secretion independent of their antimicrobial activity. In some patients with airway obstruction, the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    led to a significant reduction in bronchorrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Potential mechanisms of action may include inhibition of cholinergic neuroeffector transmission, selective inhibition of chloride secretion across airway epithelium mediated by inhibition of prostaglandin synthesis, or immunomodulation of antiinflammatory effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/63-66\">",
"     63-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prostaglandin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Airway secretion may depend partially on endogenous prostaglandins. Blockade of the cyclooxygenase pathway by the use of inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    was found to decrease the amount of expectorated sputum and to improve perceived dyspnea. The long-term effects of such therapy are unknown, and further information is needed before this treatment modality can be generalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Oscillating airflow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest physiotherapy devices that achieve airflow oscillation (such as the flutter device) have favorable effects on the viscoelasticity of sputum both in vivo and in vitro. These changes can be associated with improvements in cough and mucus clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In addition, use of a flutter device prior to delivery of inhaled medications may improve a patient's bronchodilator response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34648/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/13/1236?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/52/14148?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased tracheobronchial mucus contributes to the symptoms of COPD. General recommendations focus on the treatment of the underlying pulmonary obstructive process, airway inflammation, or infection by the use of bronchodilators, inhaled glucocorticoids, and antibiotics. Maintenance treatment with mucoactive agents is generally not associated with improved lung function and cannot be recommended in the absence of additional supportive evidence of benefit. Simple measures may include adequate hydration and trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16101?source=see_link\">",
"     guaifenesin",
"    </a>",
"    or saturated solution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    (SSKI). Nebulized",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/1/20504?source=see_link\">",
"     acetylcysteine",
"    </a>",
"    is a potent mucolytic, but its use at best must be individualized because of the potential for inducing bronchospasm. Oral acetylcysteine and carbocisteine may have a role in patients with repeated exacerbations of COPD who are not on inhaled glucocorticoids.",
"   </p>",
"   <p>",
"    Future therapies may include agents that decrease sputum adhesiveness (including surfactants), prostaglandin inhibitors, macrolide antibiotics, and new mucolytics, such as erdosteine and nacystelyn. Treatment should be individualized as certain therapeutic options shown effective in a specific disease, such as the use of hypertonic saline or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/13/29908?source=see_link\">",
"     DNase",
"    </a>",
"    in cystic fibrosis, are not be applicable to a COPD population.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/1\">",
"      Vestbo J. Epidemiological studies in mucus hypersecretion. Novartis Found Symp 2002; 248:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/2\">",
"      Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/3\">",
"      Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007; 176:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/4\">",
"      Recommendations for guidelines on clinical trials of mucoactive drugs in chronic bronchitis and chronic obstructive pulmonary disease. Task Group on Mucoactive Drugs. Chest 1994; 106:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/5\">",
"      Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care 2007; 52:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/6\">",
"      Richardson PS, Phipps RJ. The anatomy, physiology, pharmacology and pathology of tracheobronchial mucus secretion and the use of expectorant drugs in human disease. Pharmacol Ther B 1978; 3:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/7\">",
"      Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; :CD001287.",
"     </a>",
"    </li>",
"    <li>",
"     Global Initiative for Chronic Obstructive Lung Disease www.goldcopd.org (Accessed on July 04, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/9\">",
"      Randell SH, Boucher RC, University of North Carolina Virtual Lung Group. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 2006; 35:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/10\">",
"      Williams OW, Sharafkhaneh A, Kim V, et al. Airway mucus: From production to secretion. Am J Respir Cell Mol Biol 2006; 34:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/11\">",
"      Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/12\">",
"      Morgenroth K, Bolz J. Morphological features of the interaction between mucus and surfactant on the bronchial mucosa. Respiration 1985; 47:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/13\">",
"      Chen TM, Dulfano MJ. Mucus viscoelasticity and mucociliary transport rate. J Lab Clin Med 1978; 91:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/14\">",
"      Puchelle E, Zahm JM. Influence of rheological properties of human bronchial secretions on the ciliary beat frequency. Biorheology 1984; 21:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/15\">",
"      King M, Zahm JM, Pierrot D, et al. The role of mucus gel viscosity, spinnability, and adhesive properties in clearance by simulated cough. Biorheology 1989; 26:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/16\">",
"      Deneuville E, Perrot-Minot C, Pennaforte F, et al. Revisited physicochemical and transport properties of respiratory mucus in genotyped cystic fibrosis patients. Am J Respir Crit Care Med 1997; 156:166.",
"     </a>",
"    </li>",
"    <li>",
"     Yeates DB. Mucus rheology. In: The Lung. Scientific Foundations, Crystal RG, West JB (Eds), Raven Press, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/18\">",
"      Matsui H, Randell SH, Peretti SW, et al. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Invest 1998; 102:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/19\">",
"      Shim C, King M, Williams MH Jr. Lack of effect of hydration on sputum production in chronic bronchitis. Chest 1987; 92:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/20\">",
"      BARACH AL, BICKERMAN HA, BECK GJ, et al. Induced sputum as a diagnostic technique for cancer of the lungs and for mobilization of retained secretions. Arch Intern Med 1960; 106:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/21\">",
"      Clarke SW, Thomson ML, Pavia D. Effect of mucolytic and expectorant drugs on tracheobronchial clearance in chronic bronchitis. Eur J Respir Dis Suppl 1980; 110:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/22\">",
"      Pavia D, Thomson ML, Clarke SW. Enhanced clearance of secretions from the human lung after the administration of hypertonic saline aerosol. Am Rev Respir Dis 1978; 117:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/23\">",
"      King M, Dasgupta B, Tomkiewicz RP, Brown NE. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I. Am J Respir Crit Care Med 1997; 156:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/24\">",
"      Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/25\">",
"      Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/26\">",
"      Ziment I. Pharmacologic therapy of obstructive airway disease. Clin Chest Med 1990; 11:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/27\">",
"      Taube C, Holz O, M&uuml;cke M, et al. Airway response to inhaled hypertonic saline in patients with moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/28\">",
"      Feng W, Garrett H, Speert DP, King M. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro. Am J Respir Crit Care Med 1998; 157:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/29\">",
"      Bromhexine. Lancet 1971; 1:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/30\">",
"      Pavia D, Agnew JE, Glassman JM, et al. Effects of iodopropylidene glycerol on tracheobronchial clearance in stable, chronic bronchitic patients. Eur J Respir Dis 1985; 67:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/31\">",
"      Antonelli A, Carraro A, Donati C, Garrubba V. Mucolytic effects of domiodol in tracheostomized patients after total laryngectomy. Double-blind, placebo-controlled, randomized pilot study with four-month follow-up. Arzneimittelforschung 1992; 42:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/32\">",
"      Petty TL. The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990; 97:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/33\">",
"      Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest 1996; 109:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/34\">",
"      Mezey RJ, Cohn MA, Fernandez RJ, et al. Mucociliary transport in allergic patients with antigen-induced bronchospasm. Am Rev Respir Dis 1978; 118:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/35\">",
"      Foster WM, Bergofsky EH, Bohning DE, et al. Effect of adrenergic agents and their mode of action on mucociliary clearance in man. J Appl Physiol 1976; 41:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/36\">",
"      Foster WM, Bergofsky EH. Airway mucus membrane: effects of beta-adrenergic and anticholinergic stimulation. Am J Med 1986; 81:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/37\">",
"      Wanner A. Effect of ipratropium bromide on airway mucociliary function. Am J Med 1986; 81:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/38\">",
"      Annis P, Landa J, Lichtiger M. Effects of atropine on velocity of tracheal mucus in anesthetized patients. Anesthesiology 1976; 44:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/39\">",
"      Taylor RG, Pavia D, Agnew JE, et al. Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance. Thorax 1986; 41:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/40\">",
"      Sutton PP, Pavia D, Bateman JR, Clarke SW. The effect of oral aminophylline on lung mucociliary clearance in man. Chest 1981; 80:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/41\">",
"      Thompson AB, Mueller MB, Heires AJ, et al. Aerosolized beclomethasone in chronic bronchitis. Improved pulmonary function and diminished airway inflammation. Am Rev Respir Dis 1992; 146:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/42\">",
"      Fazio F, Lafortuna CL. Beclomethasone dipropionate does not affect mucociliary clearance in patients with chronic obstructive lung disease. Respiration 1986; 50:62.",
"     </a>",
"    </li>",
"    <li>",
"     Swinyard EA, Pathak MA. Surface-acting drugs. In: The Pharmacological Basis of Therapeutics, 6th ed, Goodman, Gilman (Eds), Macmillan, New York 1980.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/44\">",
"      Rao S, Wilson DB, Brooks RC, Sproule BJ. Acute effects of nebulization of N-acetylcysteine on pulmonary mechanics and gas exchange. Am Rev Respir Dis 1970; 102:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/45\">",
"      Gallon AM. Evaluation of nebulised acetylcysteine and normal saline in the treatment of sputum retention following thoracotomy. Thorax 1996; 51:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/46\">",
"      Zuin R, Palamidese A, Negrin R, et al. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 2005; 25:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/47\">",
"      Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1988; 1:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/48\">",
"      Parr GD, Huitson A. Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis. Br J Dis Chest 1987; 81:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/49\">",
"      Stey C, Steurer J, Bachmann S, et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000; 16:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/50\">",
"      Black PN, Morgan-Day A, McMillan TE, et al. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]. BMC Pulm Med 2004; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/51\">",
"      Decramer M, Rutten-van M&ouml;lken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/52\">",
"      Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee. Thorax 1985; 40:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/53\">",
"      Millar AB, Pavia D, Agnew JE, et al. Effect of oral N-acetylcysteine on mucus clearance. Br J Dis Chest 1985; 79:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/54\">",
"      Cotgreave IA, Eklund A, Larsson K, Mold&eacute;us PW. No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. Eur J Respir Dis 1987; 70:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/55\">",
"      Gillissen A, Jaworska M, Orth M, et al. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respir Med 1997; 91:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/56\">",
"      Moretti M, Bottrighi P, Dallari R, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res 2004; 30:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/57\">",
"      Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/58\">",
"      Girod S, Galabert C, Lecuire A, et al. Phospholipid composition and surface-active properties of tracheobronchial secretions from patients with cystic fibrosis and chronic obstructive pulmonary diseases. Pediatr Pulmonol 1992; 13:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/59\">",
"      De Sanctis GT, Tomkiewicz RP, Rubin BK, et al. Exogenous surfactant enhances mucociliary clearance in the anaesthetized dog. Eur Respir J 1994; 7:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/60\">",
"      Anzueto A, Jubran A, Ohar JA, et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA 1997; 278:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/61\">",
"      Vasconcellos CA, Allen PG, Wohl ME, et al. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994; 263:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/62\">",
"      Marom ZM, Goswami SK. Respiratory mucus hypersecretion (bronchorrhea): a case discussion--possible mechanisms(s) and treatment. J Allergy Clin Immunol 1991; 87:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/63\">",
"      Suez D, Szefler SJ. Excessive accumulation of mucus in children with asthma: a potential role for erythromycin? A case discussion. J Allergy Clin Immunol 1986; 77:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/64\">",
"      Tamaoki J, Tagaya E, Sakai A, Konno K. Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus. J Allergy Clin Immunol 1995; 95:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/65\">",
"      Tamaoki J, Isono K, Sakai N, et al. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J 1992; 5:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/66\">",
"      Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008; 31:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/67\">",
"      Tamaoki J, Chiyotani A, Kobayashi K, et al. Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis. Am Rev Respir Dis 1992; 145:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/68\">",
"      Tomkiewicz RP, Biviji A, King M. Effects of oscillating air flow on the rheological properties and clearability of mucous gel simulants. Biorheology 1994; 31:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/69\">",
"      App EM, Kieselmann R, Reinhardt D, et al. Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: flutter vs autogenic drainage. Chest 1998; 114:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34648/abstract/70\">",
"      Wolkove N, Kamel H, Rotaple M, Baltzan MA Jr. Use of a mucus clearance device enhances the bronchodilator response in patients with stable COPD. Chest 2002; 121:702.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1456 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34648=[""].join("\n");
var outline_f33_53_34648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROPERTIES OF MUCUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MUCOACTIVE STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Aerosols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oral expectorants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Iodide preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sodium cromoglycate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bronchodilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Beta agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Anticholinergics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Aminophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Thiols and thiol derivatives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Erdosteine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - S-carboxymethyl cysteine (carbocisteine)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Role of concomitant inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recombinant human DNase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Surfactant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Actin-severing agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prostaglandin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Oscillating airflow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/52/14148?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD) treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/11/38073?source=related_link\">",
"      Treatment of bronchiectasis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_53_34649="Pulmonary complications of cocaine abuse";
var content_f33_53_34649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary complications of cocaine abuse",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34649/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34649/contributors\">",
"     C Crawford Mechem, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34649/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34649/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34649/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34649/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/53/34649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine is an alkaloid with anesthetic properties obtained from the leaves of Erythroxylon coca, a shrub native to Central and South America, the West Indies, and Indonesia. Coca&rsquo;s unique chemical properties have led to its use in social, religious, and medicinal settings for centuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cocaine was first isolated from coca leaves in 1859. Over the following sixty years, many over-the-counter products containing cocaine were marketed, including asthma remedies and \"French Wine Cola,\" the predecessor of Coca-Cola. While a \"pinch of coca leaves\" was included in John Styth Pemberton's original 1886 recipe for Coca-Cola, the company began using decocainized leaves in 1906 when the Pure Food and Drug Act was passed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/2\">",
"     2",
"    </a>",
"    ]. The first cocaine-related fatalities were reported in 1893, and in 1914 the Harrison Narcotic Act banned the nonprescription use of cocaine-containing products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cocaine is a widely abused substance around the world. Toxicity in a variety of organs has been reported, including the cardiovascular, respiratory, and central nervous systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. The pulmonary sequelae that result from cocaine abuse will be reviewed here. Other aspects of cocaine abuse are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/39/39545?source=see_link\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The local anesthetic properties of cocaine derive from its ability to stabilize cell membranes and block neuronal sodium channels. It also has potent sympathomimetic and central nervous system stimulant effects due to interference with the reuptake of catecholamines and serotonin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cocaine hydrochloride is a heat-labile fine white powder that can be inhaled nasally (\"snorted\") or injected intravenously but cannot be smoked. However, when boiled with baking soda and water and the resultant precipitate filtered or extracted with ether or alcohol, cocaine yields a lipid-soluble, heat-stable, free-base form that can be smoked (&ldquo;free basing&rdquo;). This form is commonly called \"rock\" (because of its gross appearance) or \"crack\" (because of the characteristic crackling sound it makes when heated and smoked) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Crack cocaine may be smoked by itself through a pipe, or it may be mixed with marijuana or tobacco in cigarettes. It is rapidly absorbed through the pulmonary circulation and reaches the central nervous system within seconds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/8\">",
"     8",
"    </a>",
"    ]. Its half-life in the blood is 60 to 90 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanisms of cocaine-induced pulmonary injury include thermal airway injury, direct cellular toxicity, provocation of inflammatory damage (eg, eosinophilia, diffuse alveolar damage), barotrauma, and vasospasm leading to ischemia. Profound pulmonary arterial vasospasm can cause ventilation-perfusion lung scan abnormalities consistent with pulmonary embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because many cocaine abusers also smoke marijuana or tobacco, it is difficult to determine whether some physiologic alterations (eg, decreased diffusing capacity) or pathologic changes (eg, chronic inflammation) are specifically caused by cocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although smoking crack cocaine accounts for most cases of pulmonary toxicity, intravenous use, snorting, and \"body packing\" (the practice among smugglers of swallowing packets of cocaine to facilitate transport) have also resulted in lung damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute pulmonary toxicity and crack lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;&ldquo;Crack lung&rdquo; refers to a syndrome of diffuse alveolar damage and hemorrhagic alveolitis that occurs within 48 hours of smoking crack cocaine. This presentation is associated with diffuse alveolar hemorrhage or occasionally eosinophilia on bronchoscopy, and diffuse alveolar damage and hyaline membrane formation in biopsy or autopsy specimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The roles of particulates, nitric oxide generation, and bronchial artery constriction in the acute lung injury are not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathophysiology of acute cocaine intoxication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link&amp;anchor=H5#H5\">",
"     \"Cocaine: Acute intoxication\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31988479\">",
"    <span class=\"h2\">",
"     Acute eosinophilic pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute eosinophilic pneumonia is occasionally reported within hours to days of cocaine use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/3,9,19\">",
"     3,9,19",
"    </a>",
"    ]. In a case report, onset of an eosinophilic pleural effusion and pulmonary eosinophilia developed a few days after the second use of crack cocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/20\">",
"     20",
"    </a>",
"    ]. The mechanism by which cocaine induces pulmonary eosinophilia is not known, although cigarette smoking also appears to be a risk factor for acute eosinophilic pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29527?source=see_link\">",
"     \"Pleural fluid eosinophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1255?source=see_link&amp;anchor=H2#H2\">",
"     \"Idiopathic acute eosinophilic pneumonia\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pneumothorax and pneumomediastinum",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common practice among crack smokers is to perform a Valsalva maneuver after inhalation. Smoking partners also exhale forcefully into each other's mouths to increase uptake of the drug. These practices may lead to barotrauma followed by the development of pneumothorax, pneumomediastinum, or pneumopericardium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/13,21,22\">",
"     13,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chronic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term cocaine use is associated with a variety of histopathologic changes in the lung, including foreign body granulomatosis, bronchiectasis, and recurrent alveolar hemorrhage with hemosiderosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/7,14,15,19,23-33\">",
"     7,14,15,19,23-33",
"    </a>",
"    ]. It is speculated that these pathologic manifestations of chronic cocaine use result from direct cellular toxicity, thermal airway injury,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an inflammatory or hypersensitivity response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22790?source=see_link&amp;anchor=H2027110#H2027110\">",
"     \"Smoke inhalation\", section on 'Subsequent management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Foreign body granulomatosis is caused by inhaled or intravenous exposure to excipients such as talc (silica), cellulose,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , and cotton fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/29,34\">",
"     29,34",
"    </a>",
"    ]. The consequences of foreign body granulomatosis include hilar adenopathy, chronic interstitial lung disease, tissue infarction due to pulmonary vascular impingement by embolized material or perivascular granulomas, and bullous emphysema. The pathophysiology of foreign body granulomatosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link&amp;anchor=H2#H2\">",
"     \"Foreign body granulomatosis\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few cases of organizing pneumonia (previously known as bronchiolitis obliterans organizing pneumonia) have been described among cocaine users, but the mechanism by which cocaine might incite this type of inflammation is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/9,23\">",
"     9,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=see_link&amp;anchor=H7#H7\">",
"     \"Bronchiolitis in adults\", section on 'Proliferative bronchiolitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=see_link&amp;anchor=H2#H2\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620853\">",
"    <span class=\"h2\">",
"     Pulmonary vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine use may cause pulmonary vascular disease through foreign body granulomatosis, vasoconstrictive effects, and thromboembolic disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7304?source=see_link\">",
"     \"Pathogenesis of pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary hypertension is thought to be one of the consequences of foreign body granulomatosis, due to vascular occlusion from embolized adulterant material (eg, talc, silica, cellulose,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    ) or vascular impingement by perivascular granulomata. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link&amp;anchor=H2#H2\">",
"     \"Foreign body granulomatosis\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is thought that chronic cocaine use may also lead to pulmonary hypertension through vasoconstrictive effects on the pulmonary circulation, similar to those on the systemic circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. However, the evidence for this is conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/37-41\">",
"     37-41",
"    </a>",
"    ]. In a small number of cases, pulmonary arterial hypertension has developed in cocaine users without other clear cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In one autopsy study of 20 cocaine users, four patients had pulmonary artery medial hypertrophy of small or medium sized arteries in the absence of foreign particle microembolization or evidence of thromboembolic disease; three used intravenous injection and one oral inhalation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/40\">",
"     40",
"    </a>",
"    ]. In contrast, a separate autopsy series of 28 cocaine users found no pathologic findings suggestive of pulmonary arterial hypertension, although three had evidence of pulmonary thromboembolism and one of pulmonary infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/41\">",
"     41",
"    </a>",
"    ]. Moreover, in a case series of 10 habitual crack cocaine smokers, intravenous cocaine administration did not increase pulmonary artery pressures or pulmonary vascular resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, it appears that a small number of cocaine users develop pulmonary hypertension. However, data are insufficient to identify which individuals are at risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that upwards of 25 percent of individuals who smoke crack develop nonspecific respiratory complaints [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, cocaine use can lead to both acute and more slowly developing serious respiratory symptoms, depending on the route of use and the presence of underlying respiratory disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/11,19,25,42-44\">",
"     11,19,25,42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smoking crack cocaine can result in the acute onset of shortness of breath and cough within 48 hours of crack inhalation; some patients also have fever, chest or back pain, sputum production, or hemoptysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/11,13-16,19,33,42,45,46\">",
"     11,13-16,19,33,42,45,46",
"    </a>",
"    ]. Shortness of breath may progress rapidly to respiratory failure in patients with acute pulmonary toxicity or acute eosinophilic pneumonia.",
"   </p>",
"   <p>",
"    Among patients with asthma, snorting or smoking cocaine can cause acute and potentially life-threatening asthma exacerbations with dyspnea, wheezing, chest tightness, and cough [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/33,43,44\">",
"     33,43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic cocaine-induced pulmonary injury can cause slowly progressive dyspnea, chronic productive or nonproductive cough, and intermittent hemoptysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/11,19,25,42-44\">",
"     11,19,25,42-44",
"    </a>",
"    ]. In some patients, cough is productive of black sputum (melanoptysis). Melanoptysis is probably due to the inhalation of carbonaceous residue from materials used to ignite crack, such as matches or rags soaked with butane or alcohol. It may also relate to the practice of scraping off and resmoking the black tarry residue left in the pipe after initial use.",
"   </p>",
"   <p>",
"    The presence of thermal burns on fingers or thumbs, the result of handling crack pipes, may raise a suspicion for cocaine as an etiology for pulmonary pathology in patients denying cocaine abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A discussion of the nonpulmonary manifestations of cocaine intoxication is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link&amp;anchor=H6#H6\">",
"     \"Cocaine: Acute intoxication\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1223302\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation and diagnosis of the various cocaine-induced lung diseases typically includes complete blood count with differential, blood chemistries, blood and sputum cultures, pulmonary function testing, pulse oximetry, and chest imaging. Bronchoscopy and bronchoalveolar lavage are frequently performed when diffuse radiographic opacities are noted. Lung biopsy is occasionally required, when the radiographic pattern is atypical or the patient fails to improve with supportive care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H619968\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific laboratory findings for acute or chronic cocaine-induced pulmonary toxicity. Routine laboratory testing of patients with suspected cocaine-induced pulmonary toxicity typically includes complete blood count and differential, blood cultures, and also levels of drugs of abuse, as indicated. The main role of these tests is to exclude other causes of the clinical manifestations, although some patients with acute eosinophilic pneumonia will have eosinophilia in the peripheral blood. The evaluation of patients with acute cocaine intoxication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link&amp;anchor=H8#H8\">",
"     \"Cocaine: Acute intoxication\", section on 'Laboratory and radiographic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As cocaine use is a risk factor for HIV infection with its associated complications, HIV testing is appropriate in cocaine-using patients with respiratory complaints. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10793?source=see_link\">",
"     \"Serologic screening for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plasma D-dimer testing is commonly used as an initial test in patients suspected of having acute pulmonary embolism. Its accuracy in differentiating acute pulmonary embolism (PE) from vasoconstriction due to cocaine has not been reported, although cocaine use is associated with false positive D-dimer testing. In a prospective, observational study of 4,356 patients undergoing D-dimer measurement for possible PE, multivariate analysis identified cocaine use as a risk factor for a false positive D-dimer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role for toxicology testing for cocaine and its metabolites is limited. Cocaine is rapidly metabolized and detectable in blood and urine only briefly (ie, a few hours) after use, so a negative test does not exclude the possibility that cocaine use caused the pulmonary findings. Benzoylecgonine is the major urinary metabolite of cocaine and can be detected in the blood for two days after cocaine use and in the urine for several more days. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=see_link&amp;anchor=H30#H30\">",
"     \"Cocaine abuse and dependence in adults\", section on 'Drug testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1223514\">",
"    <span class=\"h2\">",
"     Pulmonary function testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary function testing is generally obtained as part of an evaluation of dyspnea in patients with a subacute or chronic presentation. Studies examining the effect of crack cocaine use on pulmonary function have yielded variable results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/9,49,50\">",
"     9,49,50",
"    </a>",
"    ]. In the largest study of 202 habitual users of crack cocaine, a mild, but statistically significant reduction in diffusing capacity was noted, but spirometry and lung volumes were normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/49\">",
"     49",
"    </a>",
"    ]. The cause of the mild reduction in diffusing capacity is not known, but may be related to the accumulation of hemosiderin-laden macrophages in the alveoli. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Bronchoalveolar lavage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Pulse oximetry is monitored to determine the adequacy of supplemental oxygen administration. Arterial blood gases (ABGs) are obtained to evaluate for alveolar hypoventilation (if mental status is depressed) and to assess the severity of the gas transfer abnormality. ABGs obtained in patients with acute lung injury due to cocaine usually show acute respiratory alkalosis, hypoxemia, and an elevated alveolar-arterial oxygen gradient (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?30/51/31539?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest radiograph is obtained in the majority of patients presenting with respiratory complaints in the setting of cocaine use. Abnormalities on chest radiograph among patients presenting with chest pain or dyspnea after using cocaine include atelectasis, pneumothorax, hemopneumothorax, pneumopericardium, pneumomediastinum, focal consolidation, and diffuse parenchymal ground glass or consolidative opacities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High resolution computed tomography (HRCT) of the chest is usually obtained for further evaluation of an abnormal chest radiograph. Typical findings include interlobular septal thickening, peribronchial nodules, ground glass opacities, and areas of consolidation that may evolve into cavitations (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53000 \" href=\"mobipreview.htm?17/49/18193\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/33,52\">",
"     33,52",
"    </a>",
"    ]. Patients who inject cocaine intravenously may develop foreign body granulomatosis, due to talc and other agents mixed with the cocaine. The radiographic findings of foreign body granulomatosis include small 2 to 3 mm well-defined nodules, confluent perihilar masses, and ground glass opacities; these findings are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link&amp;anchor=H85087359#H85087359\">",
"     \"Foreign body granulomatosis\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Computed tomography with pulmonary angiography (CTPA) is obtained when the acute onset of dyspnea or chest pain suggest possible pulmonary embolism. Visualization of an intraluminal filling defect by CTPA is helpful in differentiating vasoconstriction of the pulmonary arterial circulation due to cocaine from pulmonary embolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Bronchoalveolar lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;When patients present with respiratory symptoms and radiographic opacities after using cocaine, the main purpose of bronchoscopy with bronchoalveolar lavage (BAL) is to evaluate for infection, eosinophilia, and alveolar hemorrhage. Most patients with respiratory failure will undergo bronchoscopy with BAL, often immediately after intubation. In order to identify diffuse alveolar hemorrhage (DAH), BAL is performed with three sequential wedged lavages from the same segment. The presence of increasingly bloody lavage returns is diagnostic of DAH. Samples are also sent for cell counts, differential microbiologic analysis (including tests for opportunistic infections), and cytology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/41/25239?source=see_link\">",
"     \"Basic principles and technique of bronchoalveolar lavage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=see_link\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bronchoalveolar lavage findings in patients with crack lung include carbonaceous debris, eosinophils, Charcot-Leyden crystals, hemosiderin-laden macrophages, and increased cell counts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/13,25,29,45\">",
"     13,25,29,45",
"    </a>",
"    ]. Elevated BAL protein measurements suggestive of increased pulmonary vascular permeability have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/45\">",
"     45",
"    </a>",
"    ]. Asymptomatic habitual cocaine users have an increased percentage of hemosiderin-laden macrophages compared with tobacco smokers or nonsmokers, suggestive of recurrent subclinical alveolar hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/29\">",
"     29",
"    </a>",
"    ]. Extreme eosinophilia (&gt;25 percent) is indicative of eosinophilic pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1224074\">",
"    <span class=\"h2\">",
"     Lung biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with progressive symptoms and diffuse interstitial disease (without significant emphysematous changes) on chest CT scan, and an unclear diagnosis, transbronchial biopsy is often performed at the time of flexible bronchoscopy (in the absence of contraindications). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43816?source=see_link&amp;anchor=H5040289#H5040289\">",
"     \"Flexible bronchoscopy: Equipment, procedure, and complications\", section on 'Transbronchial biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=see_link&amp;anchor=H4#H4\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\", section on 'Transbronchial lung biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Video-assisted thoracoscopic or open lung biopsy is performed, when the diagnosis remains unclear after the above evaluation and the patient&rsquo;s lung function is deteriorating or severely impaired. Generally, an echocardiogram is performed prior to either of these procedures to exclude the possibility that pulmonary hypertension is the cause of dyspnea or hypoxemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of the acute onset of cocaine-induced pulmonary symptoms includes acute pulmonary toxicity from crack cocaine, acute eosinophilic pneumonia, acute respiratory distress syndrome (from infection, aspiration, and other causes), pulmonary embolism, heart failure, pneumonia, and acute coronary syndrome. The differential of chronic cocaine-induced lung toxicity and foreign body granulomatosis includes interstitial lung disease (eg, organizing pneumonia, idiopathic interstitial pneumonias, lymphangitic carcinomatosis, pneumoconioses), and granulomatous lung disease (eg, sarcoidosis, berylliosis, miliary tuberculosis), and emphysema due to cigarette smoking. These possibilities are differentiated by the results of laboratory testing, imaging studies, cultures, bronchoalveolar lavage, and occasionally lung biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5096?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of diffuse lung disease by conventional chest radiography\", section on 'Basic patterns'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the adult with interstitial lung disease: Diagnostic testing\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High resolution computed tomography (HRCT) of the chest helps to characterize the pattern of involvement. Focal consolidation is more consistent with pneumonia, pulmonary infarct, or organizing pneumonia, while diffuse ground glass or consolidative opacities are consistent with &ldquo;crack lung&rdquo; or acute respiratory distress syndrome due to other causes. Computed tomography with pulmonary angiogram (CTPA) can help differentiate thromboemboli from acute pulmonary vasoconstriction. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Imaging'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=see_link\">",
"     \"High resolution computed tomography of the lungs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23512?source=see_link\">",
"     \"The diffuse alveolar hemorrhage syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary hemorrhage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    eosinophilic pneumonia due to cocaine are identified by sequential bronchoalveolar lavage (BAL) with cell counts and cultures. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Bronchoalveolar lavage'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=see_link&amp;anchor=H16#H16\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Hemorrhagic BAL'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=see_link&amp;anchor=H12#H12\">",
"     \"Role of bronchoalveolar lavage in diagnosis of interstitial lung disease\", section on 'Eosinophilic BAL'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When an acute coronary syndrome due to the vasoconstrictive effects of cocaine is in the differential due to a combination of chest pain and dyspnea, an electrocardiogram and measurement of serum troponin I are helpful for identifying myocardial ischemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/39/39545?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation and management of the cardiovascular complications of cocaine abuse\", section on 'Evaluation of cocaine-induced chest pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In habitual cocaine users with chronic respiratory symptoms, pulmonary radiographic opacities, and no history of other exposures (eg, beryllium, silica) or clear evidence of infection, lung biopsy may be necessary to determine whether the patient has occult infection, organizing pneumonia, foreign body granulomatosis, or other non cocaine-related interstitial lung disease. Usually, video-assisted lung biopsy is performed in order to obtain a sample of sufficient size, although transbronchial biopsy may be performed first when foreign body granulomatosis is suspected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=see_link\">",
"     \"Role of lung biopsy in the diagnosis of interstitial lung disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=see_link&amp;anchor=H10#H10\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link&amp;anchor=H13#H13\">",
"     \"Foreign body granulomatosis\", section on 'Lung biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link&amp;anchor=H85087667#H85087667\">",
"     \"Foreign body granulomatosis\", section on 'Histopathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with insidious onset of dyspnea, desaturation on exertional pulse oximetry, a reduced diffusing capacity, and no evidence of radiographic parenchymal opacities, an echocardiogram is used to screen for pulmonary hypertension as an explanation of the patient&rsquo;s symptoms; right heart catheterization would be needed for confirmation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97241203\">",
"    <span class=\"h1\">",
"     COMORBIDITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97241211\">",
"    <span class=\"h2\">",
"     Pulmonary infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cocaine users, particularly crack smokers, are at increased risk for pulmonary infections. To some degree, this is a consequence of cocaine&rsquo;s depressant effects on lymphocyte and macrophage activity and mucociliary clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/7,53,54\">",
"     7,53,54",
"    </a>",
"    ]. However, much of the excess risk probably relates to the association of crack use with other behavioral patterns that predispose to pulmonary infection. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Concomitant use of narcotics or alcohol, which increase the risk of aspiration. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38439?source=see_link\">",
"       \"Overview of pulmonary disease in injection drug users\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased exposure to tuberculosis because of the crowded conditions, transient population, and frequent coughing from crack use that are found in crack houses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/9,55\">",
"       9,55",
"      </a>",
"      ]. In addition, it has been suggested that crack use may directly predispose to infection with tuberculosis by suppressing antimicrobial activity of alveolar macrophages [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased frequency of malnutrition.",
"     </li>",
"     <li>",
"      Increased risk of AIDS because of concomitant intravenous drug use or the practice of exchanging sex for drugs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10793?source=see_link\">",
"       \"Serologic screening for HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97241218\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The carcinogenicity of cocaine smoking has been much less well studied than that of tobacco smoking. Several reports have documented histologic and molecular changes in the bronchial epithelium of marijuana and cocaine smokers that are similar to the metaplastic premalignant alterations that are seen among tobacco smokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/57\">",
"     57",
"    </a>",
"    ]. Users of these drugs may be at increased risk for lung cancer, although the magnitude of risk has not been well quantified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of the pulmonary consequences of cocaine abuse is largely based on observations from case reports. Supportive care is the most important modality, along with cessation of crack cocaine use. Referral to a drug abuse treatment program is advised for all patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/58\">",
"     58",
"    </a>",
"    ]. This is particularly important in cases where lung injury has occurred secondary to chronic cocaine use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=see_link\">",
"     \"Cocaine abuse and dependence in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general management of acute cocaine intoxication is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H621418\">",
"    <span class=\"h2\">",
"     Crack lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management of crack lung is supportive to maintain adequate oxygenation while the acute lung injury resolves. Noncardiogenic pulmonary edema is treated with administration of supplemental oxygen and conservative fluid management to reduce edema fluid formation. Many patients require ventilatory support, either noninvasive positive pressure ventilation or endotracheal intubation with mechanical ventilation for respiratory failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/9\">",
"     9",
"    </a>",
"    ]. For patients with acute intoxication who require intubation, use of a nondepolarizing neuromuscular blocker, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    , is preferred over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=see_link\">",
"     \"Noncardiogenic pulmonary edema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=see_link&amp;anchor=H9#H9\">",
"     \"Cocaine: Acute intoxication\", section on 'Initial management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As the differential diagnosis of &ldquo;crack lung&rdquo; includes infections, such as community acquired pneumonia, aspiration pneumonia, and opportunistic infections (in patients with underlying AIDS), broad-spectrum antibiotics are usually initiated on presentation while awaiting culture results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/23,25,59\">",
"     23,25,59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no definitive data supporting the use of glucocorticoids for alveolar hemorrhage caused by cocaine, but case reports have described clinical and radiographic improvement with administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34649/abstract/26,52\">",
"     26,52",
"    </a>",
"    ]. It is possible that these patients had a component of eosinophilic pneumonia that responded to the glucocorticoids. The limited role of glucocorticoids in acute respiratory distress syndrome is discussed separately. (See",
"    <a class=\"local\" href=\"#H31988479\">",
"     'Acute eosinophilic pneumonia'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/52/9033?source=see_link&amp;anchor=H16#H16\">",
"     \"Novel therapies for the acute respiratory distress syndrome\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the presence of significant eosinophilia in the BAL fluid (ie, &gt;25 percent), treatment would follow that for acute eosinophilic pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1225587\">",
"    <span class=\"h2\">",
"     Acute eosinophilic pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of acute eosinophilic pneumonia in cocaine users includes complete cessation of cocaine use and supportive care with supplemental oxygen and ventilatory support, as needed. In addition, systemic glucocorticoid therapy is usually initiated, although no trials have been performed to identify the ideal dose or duration of treatment. Initial therapy is based on the severity of disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the absence of respiratory failure, initial treatment is with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &nbsp;(40 to 60 mg daily)",
"     </li>",
"     <li>",
"      In the presence of respiratory failure,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      &nbsp;(60 to 125 mg every six hours) is given intravenously until respiratory failure resolves and is then changed to oral therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of cocaine-induced acute eosinophilic pneumonia follows that for idiopathic acute eosinophilic pneumonia, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1255?source=see_link&amp;anchor=H12#H12\">",
"     \"Idiopathic acute eosinophilic pneumonia\", section on 'Treatment and outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97242881\">",
"    <span class=\"h2\">",
"     Pneumothorax, hemothorax, and pneumomediastinum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pneumothorax, hemothorax, and pneumomediastinum depends upon the severity of respiratory impairment and the size of the pneumothorax or hemothorax. All patients are provided with supportive care, including supplemental oxygen. The indications for tube thoracostomy and other treatment options for pneumothorax are discussed separately. Generally, pneumomediastinum does not require specific therapy in adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H10#H10\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'Treatment options'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620969\">",
"    <span class=\"h2\">",
"     Organizing pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When organizing pneumonia develops in association with crack cocaine use, systemic glucocorticoids are the mainstay of treatment, as in the treatment of cryptogenic organizing pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=see_link&amp;anchor=H12#H12\">",
"     \"Cryptogenic organizing pneumonia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H621681\">",
"    <span class=\"h2\">",
"     Foreign body granulomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of foreign body granulomatosis is largely supportive with cessation of drug use, administration of supplemental oxygen, and ventilatory support, as needed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link&amp;anchor=H14#H14\">",
"     \"Foreign body granulomatosis\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H620984\">",
"    <span class=\"h2\">",
"     Bronchoconstriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on clinical experience, bronchodilators, such as inhaled beta agonists, are used to treat cocaine-induced bronchoconstriction and wheezing. The general treatment of asthma exacerbations is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226405\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of vasodilator therapy in pulmonary hypertension due to foreign body granulomatosis has not been well-studied. If vasodilator testing is undertaken in this setting, it is most safely done with short acting agents and concomitant monitoring of pulmonary artery pressures and cardiac output in an experienced center. The general management of pulmonary arterial hypertension is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link&amp;anchor=H85088016#H85088016\">",
"     \"Foreign body granulomatosis\", section on 'Pulmonary hypertension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=see_link\">",
"     \"Treatment of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97240659\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226512\">",
"    <span class=\"h2\">",
"     Pathophysiology and clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cocaine hydrochloride is a heat-labile fine white powder that can be inhaled nasally (\"snorted\") or injected intravenously but cannot be smoked. However, when cocaine is boiled with baking soda and water, and the resultant precipitate filtered or extracted with ether or alcohol, the product known as &ldquo;crack cocaine&rdquo; can be smoked (&ldquo;free-basing&rdquo;). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute cocaine pulmonary toxicity occurs within 48 hours of smoking cocaine; patients typically develop a combination of fever, dyspnea, hypoxemia, and diffuse ground glass or consolidative opacities. This presentation has been termed \"crack lung.\" (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Acute pulmonary toxicity and crack lung'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other acute pulmonary complications of cocaine use include acute eosinophilic pneumonia, pneumothorax, and pneumomediastinum. (See",
"      <a class=\"local\" href=\"#H31988479\">",
"       'Acute eosinophilic pneumonia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pneumothorax and pneumomediastinum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-term cocaine exposure can result in recurrent alveolar hemorrhage, hemosiderosis, bronchiectasis, foreign body granulomatosis, hilar lymphadenopathy (due to foreign body granulomatosis), organizing pneumonia, pulmonary infarction, and bullous emphysema. Pulmonary artery hypertension and thromboembolic disease are additional potential causes of hypoxemia in chronic cocaine users. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Chronic toxicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H620853\">",
"       'Pulmonary vascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms and signs of both acute and chronic cocaine-induced pulmonary injury include fever, chest or back pain (frequently pleuritic), dyspnea, cough with or without sputum production, hyperpnea, wheezing (potentially life-threatening exacerbations in patients with a history of asthma), hemoptysis, melanoptysis (expectoration of black sputum), and finger burns. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226520\">",
"    <span class=\"h2\">",
"     Diagnosis and management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of the various cocaine-induced lung diseases is based upon a history of cocaine use and compatible clinical, radiographic, and bronchoscopic findings. Most patients with acute respiratory failure and radiographic opacities suggestive of &ldquo;crack lung&rdquo; will undergo bronchoscopy and sequential bronchoalveolar lavage (BAL). BAL samples are sent for cell counts, differential, microbiologic analysis, and cytology. (See",
"      <a class=\"local\" href=\"#H1223302\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with persistent respiratory symptoms, pulmonary radiographic opacities, and no clear evidence of infection or pulmonary eosinophilia, lung biopsy is sometimes performed to determine whether the patient has occult infection, organizing pneumonia, foreign body granulomatosis, or other non cocaine-related interstitial lung disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of &ldquo;crack lung&rdquo; is largely supportive following the usual measures for acute lung injury, with administration of supplemental oxygen, bronchodilator therapy (when wheezing is present), and noninvasive or invasive mechanical ventilation when indicated. Broad spectrum antibiotics are usually administered pending the results of microbiologic investigations. (See",
"      <a class=\"local\" href=\"#H621418\">",
"       'Crack lung'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9065?source=see_link\">",
"       \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest NOT using glucocorticoids in the routine management of &ldquo;crack lung,&rdquo; unless there is evidence of eosinophilia in the peripheral blood or BAL fluid (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In the presence of significant eosinophilia in the BAL fluid (&gt;25 percent), we suggest following the treatment regimen for idiopathic acute eosinophilic pneumonia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H621418\">",
"       'Crack lung'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1225587\">",
"       'Acute eosinophilic pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Discussions of the management of pneumothorax, acute eosinophilic pneumonia, organizing pneumonia, foreign body granulomatosis, exacerbations of asthma, and pulmonary hypertension are provided separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1255?source=see_link&amp;anchor=H12#H12\">",
"       \"Idiopathic acute eosinophilic pneumonia\", section on 'Treatment and outcome'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=see_link&amp;anchor=H12#H12\">",
"       \"Cryptogenic organizing pneumonia\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=see_link&amp;anchor=H14#H14\">",
"       \"Foreign body granulomatosis\", section on 'Management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/56/5002?source=see_link\">",
"       \"Treatment of acute exacerbations of asthma in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=see_link\">",
"       \"Treatment of pulmonary hypertension in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link\">",
"       \"Placement and management of thoracostomy tubes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prevention of chronic pulmonary toxicity requires cessation of crack cocaine use; referral to a drug abuse treatment program is advised for all patients. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/1\">",
"      Indriati E, Buikstra JE. Coca chewing in prehistoric coastal Peru: dental evidence. Am J Phys Anthropol 2001; 114:242.",
"     </a>",
"    </li>",
"    <li>",
"     Haubrich WS. Medical Meanings. American College of Physicians, Philadelphia, 1997. p. 48.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/3\">",
"      Albertson TE, Walby WF, Derlet RW. Stimulant-induced pulmonary toxicity. Chest 1995; 108:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/4\">",
"      Warner EA. Cocaine abuse. Ann Intern Med 1993; 119:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/5\">",
"      Nadeem S, Nasir N, Israel RH. L&ouml;ffler's syndrome secondary to crack cocaine. Chest 1994; 105:1599.",
"     </a>",
"    </li>",
"    <li>",
"     Lewin NA, Goldfrank LR, Hoffman RS. Cocaine. In: Toxicologic Emergencies, 5th ed, Goldfrank LR, Flomenbaum NE, Lewin NA, et al (Eds), Appleton and Lange, Norwalk CT 1994. p.847.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/7\">",
"      Thadani PV. NIDA conference report on cardiopulmonary complications of \"crack\" cocaine use. Clinical manifestations and pathophysiology. Chest 1996; 110:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/8\">",
"      Baldwin GC, Buckley DM, Roth MD, et al. Acute activation of circulating polymorphonuclear neutrophils following in vivo administration of cocaine. A potential etiology for pulmonary injury. Chest 1997; 111:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/9\">",
"      Haim DY, Lippmann ML, Goldberg SK, Walkenstein MD. The pulmonary complications of crack cocaine. A comprehensive review. Chest 1995; 107:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/10\">",
"      Ramachandaran S, Khan AU, Dadaparvar S, Sherman MS. Inhalation of crack cocaine can mimic pulmonary embolism. Clin Nucl Med 2004; 29:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/11\">",
"      Heffner JE, Harley RA, Schabel SI. Pulmonary reactions from illicit substance abuse. Clin Chest Med 1990; 11:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/12\">",
"      Kleerup EC, Koyal SN, Marques-Magallanes JA, et al. Chronic and acute effects of \"crack\" cocaine on diffusing capacity, membrane diffusion, and pulmonary capillary blood volume in the lung. Chest 2002; 122:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/13\">",
"      Kissner DG, Lawrence WD, Selis JE, Flint A. Crack lung: pulmonary disease caused by cocaine abuse. Am Rev Respir Dis 1987; 136:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/14\">",
"      Delaney K, Hoffman RS. Pulmonary infarction associated with crack cocaine use in a previously healthy 23-year-old woman. Am J Med 1991; 91:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/15\">",
"      Forrester JM, Steele AW, Waldron JA, Parsons PE. Crack lung: an acute pulmonary syndrome with a spectrum of clinical and histopathologic findings. Am Rev Respir Dis 1990; 142:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/16\">",
"      McCormick M, Nelson T. Cocaine-induced fatal acute eosinophilic pneumonia: a case report. WMJ 2007; 106:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/17\">",
"      Devlin RJ, Henry JA. Clinical review: Major consequences of illicit drug consumption. Crit Care 2008; 12:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/18\">",
"      Maybauer MO, Rehberg S, Traber DL, et al. [Pathophysiology of acute lung injury in severe burn and smoke inhalation injury]. Anaesthesist 2009; 58:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/19\">",
"      Oh PI, Balter MS. Cocaine induced eosinophilic lung disease. Thorax 1992; 47:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/20\">",
"      Strong DH, Westcott JY, Biller JA, et al. Eosinophilic \"empyema\" associated with crack cocaine use. Thorax 2003; 58:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/21\">",
"      Maeder M, Ullmer E. Pneumomediastinum and bilateral pneumothorax as a complication of cocaine smoking. Respiration 2003; 70:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/22\">",
"      Janes SM, Ind PW, Jackson J. Images in Thorax. Crack inhalation induced pneumomediastinum. Thorax 2004; 59:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/23\">",
"      Patel RC, Dutta D, Schonfeld SA. Free-base cocaine use associated with bronchiolitis obliterans organizing pneumonia. Ann Intern Med 1987; 107:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/24\">",
"      O'Donnell AE, Mappin FG, Sebo TJ, Tazelaar H. Interstitial pneumonitis associated with \"crack\" cocaine abuse. Chest 1991; 100:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/25\">",
"      Klinger JR, Bensadoun E, Corrao WM. Pulmonary complications from alveolar accumulation of carbonaceous material in a cocaine smoker. Chest 1992; 101:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/26\">",
"      Murray RJ, Albin RJ, Mergner W, Criner GJ. Diffuse alveolar hemorrhage temporally related to cocaine smoking. Chest 1988; 93:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/27\">",
"      Janjua TM, Bohan AE, Wesselius LJ. Increased lower respiratory tract iron concentrations in alkaloidal (\"crack\") cocaine users. Chest 2001; 119:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/28\">",
"      van der Klooster JM, Grootendorst AF. Severe bullous emphysema associated with cocaine smoking. Thorax 2001; 56:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/29\">",
"      Baldwin GC, Choi R, Roth MD, et al. Evidence of chronic damage to the pulmonary microcirculation in habitual users of alkaloidal (\"crack\") cocaine. Chest 2002; 121:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/30\">",
"      Bailey ME, Fraire AE, Greenberg SD, et al. Pulmonary histopathology in cocaine abusers. Hum Pathol 1994; 25:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/31\">",
"      Terra Filho M, Yen CC, Santos Ude P, Mu&ntilde;oz DR. Pulmonary alterations in cocaine users. Sao Paulo Med J 2004; 122:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/32\">",
"      Solaini L, Solini L, Gourgiotis S, et al. Bilateral pneumothorax, lung cavitations, and pleural empyema in a cocaine addict. Gen Thorac Cardiovasc Surg 2008; 56:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/33\">",
"      Restrepo CS, Carrillo JA, Mart&iacute;nez S, et al. Pulmonary complications from cocaine and cocaine-based substances: imaging manifestations. Radiographics 2007; 27:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/34\">",
"      Oubeid M, Bickel JT, Ingram EA, Scott GC. Pulmonary talc granulomatosis in a cocaine sniffer. Chest 1990; 98:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/35\">",
"      Salvi SS. Alpha1-adrenergic hypothesis for pulmonary hypertension. Chest 1999; 115:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/36\">",
"      de Jesus Perez V, Kudelko K, Snook S, Zamanian RT. Drugs and toxins-associated pulmonary arterial hypertension: lessons learned and challenges ahead. Int J Clin Pract Suppl 2011; :8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/37\">",
"      Yakel DL Jr, Eisenberg MJ. Pulmonary artery hypertension in chronic intravenous cocaine users. Am Heart J 1995; 130:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/38\">",
"      Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006; 130:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/39\">",
"      Kleerup EC, Wong M, Marques-Magallanes JA, et al. Acute effects of intravenous cocaine on pulmonary artery pressure and cardiac index in habitual crack smokers. Chest 1997; 111:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/40\">",
"      Murray RJ, Smialek JE, Golle M, Albin RJ. Pulmonary artery medial hypertrophy in cocaine users without foreign particle microembolization. Chest 1989; 96:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/41\">",
"      Rajab R, Stearns E, Baithun S. Autopsy pathology of cocaine users from the Eastern district of London: a retrospective cohort study. J Clin Pathol 2008; 61:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/42\">",
"      Tashkin DP, Gorelick D, Khalsa ME, et al. Respiratory effects of cocaine freebasing among habitual cocaine users. J Addict Dis 1992; 11:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/43\">",
"      Rubin RB, Neugarten J. Cocaine-associated asthma. Am J Med 1990; 88:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/44\">",
"      Rome LA, Lippmann ML, Dalsey WC, et al. Prevalence of cocaine use and its impact on asthma exacerbation in an urban population. Chest 2000; 117:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/45\">",
"      Cucco RA, Yoo OH, Cregler L, Chang JC. Nonfatal pulmonary edema after \"freebase\" cocaine smoking. Am Rev Respir Dis 1987; 136:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/46\">",
"      Tashkin DP. Airway effects of marijuana, cocaine, and other inhaled illicit agents. Curr Opin Pulm Med 2001; 7:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/47\">",
"      Gatof D, Albert RK. Bilateral thumb burns leading to the diagnosis of crack lung. Chest 2002; 121:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/48\">",
"      Kabrhel C, Mark Courtney D, Camargo CA Jr, et al. Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med 2010; 17:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/49\">",
"      Tashkin DP, Khalsa ME, Gorelick D, et al. Pulmonary status of habitual cocaine smokers. Am Rev Respir Dis 1992; 145:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/50\">",
"      Tashkin DP, Simmons MS, Coulson AH, et al. Respiratory effects of cocaine \"freebasing\" among habitual users of marijuana with or without tobacco. Chest 1987; 92:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/51\">",
"      Eurman DW, Potash HI, Eyler WR, et al. Chest pain and dyspnea related to \"crack\" cocaine smoking: value of chest radiography. Radiology 1989; 172:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/52\">",
"      Man&ccedil;ano A, Marchiori E, Zanetti G, et al. Pulmonary complications of crack cocaine use: high-resolution computed tomography of the chest. J Bras Pneumol 2008; 34:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/53\">",
"      Baldwin GC, Tashkin DP, Buckley DM, et al. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med 1997; 156:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/54\">",
"      Roth MD, Whittaker K, Salehi K, et al. Mechanisms for impaired effector function in alveolar macrophages from marijuana and cocaine smokers. J Neuroimmunol 2004; 147:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/55\">",
"      Leonhardt KK, Gentile F, Gilbert BP, Aiken M. A cluster of tuberculosis among crack house contacts in San Mateo County, California. Am J Public Health 1994; 84:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/56\">",
"      Story A, Bothamley G, Hayward A. Crack cocaine and infectious tuberculosis. Emerg Infect Dis 2008; 14:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/57\">",
"      Barsky SH, Roth MD, Kleerup EC, et al. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J Natl Cancer Inst 1998; 90:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/58\">",
"      Warner EA, Kosten TR, O'Connor PG. Pharmacotherapy for opioid and cocaine abuse. Med Clin North Am 1997; 81:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34649/abstract/59\">",
"      Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4343 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-F708DC0240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34649=[""].join("\n");
var outline_f33_53_34649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H97240659\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute pulmonary toxicity and crack lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31988479\">",
"      Acute eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pneumothorax and pneumomediastinum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chronic toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H620853\">",
"      Pulmonary vascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1223302\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H619968\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1223514\">",
"      Pulmonary function testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1224074\">",
"      Lung biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97241203\">",
"      COMORBIDITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97241211\">",
"      Pulmonary infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97241218\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H621418\">",
"      Crack lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1225587\">",
"      Acute eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97242881\">",
"      Pneumothorax, hemothorax, and pneumomediastinum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H620969\">",
"      Organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H621681\">",
"      Foreign body granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H620984\">",
"      Bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1226405\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97240659\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1226512\">",
"      Pathophysiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1226520\">",
"      Diagnosis and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4343\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4343|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?17/49/18193\" title=\"diagnostic image 1\">",
"      Talc granulomatosis CT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?30/51/31539?source=related_link\" title=\"calculator 1\">",
"      Calculator: A-a gradient (alveolar-arterial gradient; AaG)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/18/16681?source=related_link\">",
"      Approach to the adult with interstitial lung disease: Diagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/41/25239?source=related_link\">",
"      Basic principles and technique of bronchoalveolar lavage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24247?source=related_link\">",
"      Bronchiolitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32970?source=related_link\">",
"      Cocaine abuse and dependence in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/60/19402?source=related_link\">",
"      Cryptogenic organizing pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/39/39545?source=related_link\">",
"      Evaluation and management of the cardiovascular complications of cocaine abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/62/5096?source=related_link\">",
"      Evaluation of diffuse lung disease by conventional chest radiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43816?source=related_link\">",
"      Flexible bronchoscopy: Equipment, procedure, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/39/31353?source=related_link\">",
"      Foreign body granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/29/16858?source=related_link\">",
"      High resolution computed tomography of the lungs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1255?source=related_link\">",
"      Idiopathic acute eosinophilic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12744?source=related_link\">",
"      Internal concealment of drugs of abuse (body packing)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/57/1944?source=related_link\">",
"      Noncardiogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/52/9033?source=related_link\">",
"      Novel therapies for the acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38439?source=related_link\">",
"      Overview of pulmonary disease in injection drug users",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7304?source=related_link\">",
"      Pathogenesis of pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29527?source=related_link\">",
"      Pleural fluid eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/36/16968?source=related_link\">",
"      Role of bronchoalveolar lavage in diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/424?source=related_link\">",
"      Role of lung biopsy in the diagnosis of interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22790?source=related_link\">",
"      Smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/61/23512?source=related_link\">",
"      The diffuse alveolar hemorrhage syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_53_34650="Management of locoregional recurrence of breast cancer after breast conserving therapy";
var content_f33_53_34650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of locoregional recurrence of breast cancer after breast conserving therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34650/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34650/contributors\">",
"     Ariel Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34650/contributors\">",
"     Lisa A Kachnic, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34650/contributors\">",
"     Michael S Sabel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34650/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34650/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34650/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34650/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/53/34650/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34650/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/53/34650/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/53/34650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After breast conserving therapy (BCT), defined as a partial mastectomy (breast conserving surgery) followed by whole breast irradiation, breast cancer can recur locally, regionally,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    at distant metastatic sites. A local recurrence is defined as reappearance of cancer in the ipsilateral preserved breast. In contrast, a regional recurrence denotes tumor involving the regional lymph nodes, usually ipsilateral axillary or supraclavicular, less commonly infraclavicular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    internal mammary.",
"   </p>",
"   <p>",
"    The primary management of breast cancer has changed considerably over the past decade, and this may alter the incidence, presentation, and management of locoregional recurrences. With advances in systemic adjuvant therapy that have led to better survival rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/1\">",
"     1",
"    </a>",
"    ], more isolated locoregional recurrences, sometimes delayed for several years, may become apparent. The increasing use of neoadjuvant or induction chemotherapy to allow for breast conservation, as well as the increasing popularity of partial breast irradiation, may also affect local recurrence rates. Furthermore, the use of sentinel lymph node (SLN) biopsy rather than axillary lymph node dissection (ALND) as a method of staging the axilla may not only impact on the incidence of regional recurrence, but it has also altered the approach to the patient with an isolated locoregional recurrence.",
"   </p>",
"   <p>",
"    Aggressive multimodality treatment has the potential to provide long-term disease control for many patients who develop an isolated locoregional recurrence after BCT. Multidisciplinary evaluation and management of these cases appears to improve patient outcome and overall satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of a locoregional recurrence after BCT for operable breast cancer will be reviewed here. The management of a locoregional recurrence after mastectomy, patterns of recurrence, as well as recommendations for post-treatment surveillance, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=see_link\">",
"     \"Management of locoregional recurrence of breast cancer after mastectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8202?source=see_link\">",
"     \"Patterns of relapse and long-term complications of therapy in breast cancer survivors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link\">",
"     \"Approach to the long-term survivor of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE AND CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 to 15 percent of patients undergoing BCT for operable breast cancer will develop a locoregional recurrence within 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. This risk is only slightly higher than that of a locoregional recurrence following mastectomy (5 to 10 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=see_link\">",
"     \"Management of locoregional recurrence of breast cancer after mastectomy\"",
"    </a>",
"    .) Although rarely used anymore, individuals who undergo breast conserving surgery (BCS) alone without RT have much higher local recurrence rates compared to those who receive RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also differences in the time course and clinical features of a local recurrence after BCT and after mastectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrences tend to occur later after BCT than after mastectomy (median three to four years versus two to three years, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/7-11\">",
"       7-11",
"      </a>",
"      ]. The time to recurrence may be even longer (five to seven years) after BCT in patients who receive adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Postmastectomy recurrences are typically diagnosed by physical examination; in contrast, many in breast tumor recurrences (IBTRs) after BCT are detected by mammography alone.",
"     </li>",
"     <li>",
"      A chest wall recurrence after mastectomy is usually reflective of recurrent disease. In contrast, the reappearance of disease in an ipsilateral preserved breast can represent either a local recurrence of the initial cancer or a second primary tumor. Ipsilateral new primary breast cancers tend to develop later in the follow-up period than do true local recurrences, and the prognosis is more favorable. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'True recurrence versus second primary tumor'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Although some data sets describe a similar overall prognosis for locoregional disease recurrence after mastectomy, as compared to BCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/7\">",
"       7",
"      </a>",
"      ], postmastectomy failures are more likely to involve regional nodes, and these cases are associated with higher rates of simultaneous distant metastases and poorer cause-specific survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Local recurrence after BCT may be either invasive or in situ cancer. For patients who were initially treated for invasive disease, more than 80 percent of locoregional recurrences are invasive; the remainder are noninvasive (intraductal) lesions. Approximately 75 percent are isolated to the breast and clinically solitary; 5 and 15 percent present with a simultaneous regional nodal recurrence, and another 5 to 15 percent have distant metastases at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/9,11,14-16\">",
"     9,11,14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, for patients initially treated for in situ cancer (ductal carcinoma in situ, DCIS), approximately one-half will recur with invasive disease, whereas the remainder will have a recurrence of DCIS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37561?source=see_link&amp;anchor=H18124317#H18124317\">",
"     \"Ductal carcinoma in situ: Treatment and prognosis\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     True recurrence versus second primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical classification of an IBTR following BCT is determined by its location relative to the original tumor:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A true recurrence is within the primary tumor site or the boost volume of the treated breast.",
"     </li>",
"     <li>",
"      A marginal miss is defined as near but not within the boost volume.",
"     </li>",
"     <li>",
"      Recurrences in other quadrants (remote to the quadrant containing the original primary cancer).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After BCT, the largest fraction of IBTRs (50 to 90 percent) occur in the same quadrant as the original tumor, representing a true recurrence or marginal miss. As the interval from initial diagnosis lengthens, recurrences are more likely in other quadrants of the breast, likely representing mainly new primary tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/15,18-20\">",
"     15,18-20",
"    </a>",
"    ]. In one series, the time interval between the original primary tumor and the IBTR was considerably longer for new primaries compared to true recurrences (7.3 versus 3.7 years, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distinction between a recurrence of the original tumor versus a new primary is generally made on clinical grounds (ie, histologic subtype, location, mammographic appearance, hormone receptor status, HER2 overexpression, discordant DNA flow cytometry) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/8,20-23\">",
"     8,20-23",
"    </a>",
"    ]. In many [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/8,20,23-25\">",
"     8,20,23-25",
"    </a>",
"    ] but not all series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/16,26,27\">",
"     16,26,27",
"    </a>",
"    ], second primary tumors are associated with more favorable outcomes than true recurrences. As an example, one report included 126 patients with an IBTR after BCT, 48 of which were classified as a new primary and 78 as a true recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/20\">",
"     20",
"    </a>",
"    ]. The patients with second primary tumors had significantly better ten-year rates of cause-specific survival (83 versus 49 percent), distant disease-free survival (77 versus 26 percent), and local recurrence (2 versus 18 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8202?source=see_link&amp;anchor=H1199208#H1199208\">",
"     \"Patterns of relapse and long-term complications of therapy in breast cancer survivors\", section on 'Second primary breast tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least some data suggest that molecular classification is a more reliable method for distinguishing a true (ie, genetically related), prognostically less favorable recurrence versus a genetically distinct second primary tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In both series, patients who were identified by molecular testing as having a recurrent rather than second primary breast cancer were at significantly higher risk for distant metastatic disease. Although these data suggest the potential for tailoring therapy based upon molecular classification in the future, ipsilateral second primary tumors are not treated differently from true recurrences at present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR A LOCAL RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most important predictors of increased risk for IBTR after BCS are the use of RT and pathologic margin status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Importance of RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT is considered a standard component of BCT for the majority of women with invasive breast cancer or DCIS. As such, RT is routinely recommended, and its elimination as a component of BCT is a major risk factor for both recurrence and mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link\">",
"     \"Role of radiation therapy in breast conservation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Margin status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with negative excision margins (typically defined by the National Surgical Adjuvant Breast and Bowel Project [NSABP] as the absence of either invasive or intraductal disease at the inked margin) have lower rates of IBTR compared to those who have involved margins. In one series, the local control rate was 100 percent among patients with negative margins, versus 78 percent for those without negative margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/30\">",
"     30",
"    </a>",
"    ]. These and other data sets emphasize the importance of obtaining pathologic tumor-free margins. Positive or unknown histologic margins should prompt reexcision, since such patients are at higher risk for local recurrence even when RT is administered.",
"   </p>",
"   <p>",
"    Less clear are cases where the margin is reported as \"close\". The definition of a \"close\" margin is controversial, but most describe cancer cells to be pathologically present within 1 to 2 mm of the inked surface. Although some studies suggest a higher rate of local recurrence at 10 years in women with \"close\" margins, the number of patients in these series and the duration of follow-up are limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=see_link&amp;anchor=H15#H15\">",
"     \"Breast conserving therapy\", section on 'Margins of resection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other risk factors for local recurrence after BCT are the presence of an extensive intraductal component within the tumor in individuals who do not have negative resection margins, younger patient age, tumor size, and hormone receptor status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/5\">",
"     5",
"    </a>",
"    ]. Whether an inherited susceptibility to breast cancer or the presence of lobular cancer in situ (LCIS) at the resection margins increases the risk of a local recurrence is controversial. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=see_link&amp;anchor=H23#H23\">",
"     \"Breast conserving therapy\", section on 'Local recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND PRETREATMENT EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Presenting signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;IBTRs are generally detected either by finding a palpable mass on physical examination or as a change on posttreatment surveillance mammography. In modern series, local recurrences are detected by mammography alone approximately 40 to 75 percent of the time, by physical examination alone in 10 to 30 percent, a combination of mammography and physical examination in 10 to 25 percent, and by other imaging modalities (eg, MRI) in 5 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/31-35\">",
"     31-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both RT and surgery can lead to changes in the breast, such as mass-like fibrosis, that can be difficult to distinguish from a local recurrence on physical examination. Furthermore, the findings associated with a local recurrence may be subtle, particularly if the primary tumor was an infiltrating lobular cancer. In such cases, a local recurrence may be associated with only minimal thickening or retraction of the biopsy site without a mass. Any change in the examination more than one or two years after completion of RT must be viewed as suspicious for recurrence and worked up. Since approximately one-half of IBTRs detected on physical examination are mammographically occult, a normal mammogram in the face of a change on physical examination does not rule out the possibility of a local recurrence.",
"   </p>",
"   <p>",
"    Because mammographic sensitivity may be limited for detection of recurrent disease in an architecturally changed breast, there has been significant interest in adjunctive imaging strategies such as breast MRI. There are accumulating reports of MRI-detected, mammographically occult breast cancer recurrences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/36-44\">",
"     36-44",
"    </a>",
"    ]. However, although MRI is more sensitive than is mammography, it is less specific, resulting in more false-positive biopsies. As a result, the use of MRI as a surveillance tool or in the work-up of a suspected recurrence is controversial and still under investigation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link&amp;anchor=H560048#H560048\">",
"     \"Approach to the long-term survivor of breast cancer\", section on 'Breast imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, local recurrences after BCT are inflammatory or extensively involve the skin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. Often, these are misdiagnosed as postoperative infection. Any patient with a history of breast cancer and new inflammatory-type changes in the breast (erythema, warmth, peau d'orange appearance) who does not respond readily to antibiotics should undergo a biopsy to rule out recurrence disease. In general, these patients have a poor prognosis.",
"   </p>",
"   <p>",
"    Patients may also present with signs or symptoms of a regional recurrence, the clinical picture of which may be changing with the increasing use of sentinel lymph node biopsy. Many patients present with palpable adenopathy in the axilla or supraclavicular fossa, although a regional recurrence may also present with pain in either location or the new onset of brachial plexopathy or lymphedema of the arm. These may occur in the absence of palpable adenopathy. Any patient who develops new onset lymphedema following breast cancer treatment should be evaluated for the possibility of a regional recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any new clinical or radiographic finding after BCT for operable breast cancer should prompt a biopsy. Fine needle aspiration (FNA) biopsy is a simple and accurate method for differentiating scar from recurrent carcinoma. However, tissue biopsy (core needle or excisional) may be needed not only to confirm the diagnosis of a local recurrence, but also to assay the tumor tissue for hormone receptors and HER2 overexpression, factors which are important for treatment decisions regarding adjuvant chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hormonal therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=see_link\">",
"     \"HER2 and predicting response to therapy in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19194?source=see_link\">",
"     \"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Staging workup",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with an invasive local recurrence after BCT should have complete restaging to rule out distant metastases. At a minimum, this should include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood tests, including a complete blood count and liver function tests.",
"     </li>",
"     <li>",
"      Radionuclide bone scan, even in asymptomatic patients, as bone is the most common site of metastatic disease.",
"     </li>",
"     <li>",
"      CT of the chest, abdomen, and pelvis to screen for sites of metastatic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. The most common site of unsuspected disease is in the internal mammary lymph nodes.",
"     </li>",
"     <li>",
"      For patients with symptoms of a brachial plexopathy or arm edema without obvious adenopathy, contrast-enhanced MRI can help in the distinction between tumor recurrence versus radiation-induced fibrosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38437?source=see_link&amp;anchor=H4#H4\">",
"       \"Complications of peripheral nerve irradiation\", section on 'Late-delayed brachial plexopathy'",
"      </a>",
"      .) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increasingly, PET scans and hybrid",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      are being used in lieu of bone scintigraphy and dedicated CT scanning to survey the entire body for sites of distant metastatic spread (but not brain involvement) in patients with suspected recurrent breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/53-58\">",
"       53-58",
"      </a>",
"      ]. PET scans are more sensitive than conventional imaging such as CT, and the detection of unsuspected metastatic disease may alter the therapeutic plan. However, PET scans are limited by a high false positive rate (approximately 11 percent in a pooled analysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/59\">",
"       59",
"      </a>",
"      ]), which may lead to additional imaging studies and biopsies. PET scans should be used selectively, with tissue confirmation of distant disease before altering the treatment plan.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93609717\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE BREAST",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of ipsilateral breast tumor recurrence (IBTR) depends upon the management of the initial primary breast cancer (with or without RT),",
"    <span class=\"nowrap\">",
"     presence/absence",
"    </span>",
"    of metastatic breast cancer, and the overall medical condition of the patient. A mastectomy is the standard of care for most with a local recurrence; however, a repeat breast conserving surgery (BCS) approach is feasible for select patients who request breast conservation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Breast conserving surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mastectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard approach for an IBTR after BCS and RT is mastectomy, provided there is no evidence of distant metastatic disease. Most series report an operability rate of approximately 85 percent; reasons for nonoperability include simultaneous distant metastases, locally extensive recurrences, or inoperable regional nodal disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/15,46,60,61\">",
"     15,46,60,61",
"    </a>",
"    ]. For patients with distant disease, mastectomy can be offered as a palliative procedure.",
"   </p>",
"   <p>",
"    Patients with skin involvement or an inflammatory type of recurrence have a poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. These individuals, as well as those with locally fixed or large tumors are usually treated with systemic therapy prior to locoregional therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/45,48,62\">",
"     45,48,62",
"    </a>",
"    ]. In contrast, in patients with less aggressive local disease, adjuvant chemotherapy did not improve local control following mastectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Role of systemic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Local regional control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastectomy at the time of breast cancer recurrence does not prevent further recurrence involving the chest wall. The local regional control rate, defined as the absence of further recurrence of breast or chest-wall cancer following a mastectomy ranges from 48 to 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/9,15,16,18,19,63-70\">",
"     9,15,16,18,19,63-70",
"    </a>",
"    ]. The likelihood of a second recurrence is dependent upon the histology of the first recurrence. For example, a review of 123 patients with IBRT undergoing mastectomy found that patients with an invasive first recurrence were significantly more likely to experience a second local recurrence compared with patients with a noninvasive or focally invasive first recurrence (51 of 99 patients [52 percent] versus 0 of 24 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93611195\">",
"    <span class=\"h3\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with an isolated local recurrence will survive at least ten years; however, isolated local recurrence can be a harbinger of distant disease and early breast cancer related death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Contemporary studies report ten-year overall survival rates range from 39 to 80 percent and the distant disease-free survival rates range from 36 to 78 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/9,18,19,25,67,68,73\">",
"     9,18,19,25,67,68,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall and disease-free survival is associated with an invasive histologic recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/25,73\">",
"     25,73",
"    </a>",
"    ], two years or less time from initial treatment to recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/5,18,22,64,67,74-78\">",
"     5,18,22,64,67,74-78",
"    </a>",
"    ], and local extensiveness of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/25,46,47,67\">",
"     25,46,47,67",
"    </a>",
"    ]. The following studies illustrate these findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An invasive recurrence is poor prognostic factor. In a retrospective review of 266 patients with IBTR, patients who developed an invasive local recurrence (n=241) had a worse five-year overall survival rate and recurrence-free survival rate prognosis compared with those with a noninvasive recurrence (61 versus 95 percent, and 47 versus 94 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"     <li>",
"      A short disease-free interval between initial BCT and local recurrence is a poor prognostic factor. In a study of 2669 patients assigned to National Surgical Adjuvant Breast and Bowel Project node-positive protocols, patients with a local recurrence two years or less from the time of BCT had a significantly poorer five-year overall survival compared with women with a longer interval (49 versus 85 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/5\">",
"       5",
"      </a>",
"      ]. The distant disease survival was also poorer for patients with a short interval for local recurrence (41 versus 72 percent). The rates of distant disease were 92, 53, and 22 percent when the interval from primary treatment was less than two, two to five, and longer than five years, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/78\">",
"       78",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"     <li>",
"      Skin involvement and extensive local recurrence are negative prognostic factors. Patients with a skin recurrence had a significantly higher five-year actuarial rate of development of distant diseases compared with patients with a recurrence that did not include the skin (60 versus 39 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/47\">",
"       47",
"      </a>",
"      ]. Patients with a local recurrence identified by physical examination had a significantly shorter five-year disease-free survival compared with patients with detection by mammography alone (73 versus 91 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors associated with a poorer prognosis following a mastectomy for an isolated IBTR include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age 35 years and younger at initial diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"     <li>",
"      A disease-free interval from mastectomy to distant relapse less than two years is a poor prognosticator. Patients who remained disease free for at least two years after a mastectomy were significantly more likely to survive five years compared with patients with distant relapse within two years (50 versus 35 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     RT after mastectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data that address the benefit of chest wall or regional nodal irradiation after postrecurrence mastectomy. Irradiation of the regional nodes is an option in the uncommon scenario of a patient who did not initially undergo regional nodal irradiation at the time of BCT and who is found to have four or more positive nodes, tumor size &ge;5 cm, or perinodal fat extension at the time of postrecurrence mastectomy. We do not routinely re-irradiate the chest wall if whole breast RT was performed initially. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Breast conserving surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat breast conserving therapy (BCS) with or without breast radiation is an investigational alternative to mastectomy for patients who experience a local recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/19,69,70,79,80\">",
"     19,69,70,79,80",
"    </a>",
"    ]. This approach may be an option for select patients including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Primary breast cancer treated with BCS without radiation",
"      </strong>",
"      &ndash; Patients who underwent BCS alone (without breast RT) may be candidates for repeat BCS followed by RT. In a retrospective review of 79 patients who underwent partial mastectomy, those treated with RT (n=19) had a significantly better five-year actuarial local control rate compared with patients treated without RT (n=27) (82 versus 32 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/81\">",
"       81",
"      </a>",
"      ]. Patients treated with a total mastectomy or a total mastectomy plus RT had local control rates of 60 and 52 percent, respectively.",
"     </li>",
"     <li>",
"      <strong>",
"       Primary breast cancer treated with BCS and radiation &ndash;",
"      </strong>",
"      In the absence of randomized trials to identify appropriate candidates for repeat BCS, suggested criteria for this approach include patients with any of the following [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/19,80,82,83\">",
"       19,80,82,83",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A localized recurrence confined to the biopsy site with concordance between mammogram and physical examination.",
"     </li>",
"     <li>",
"      Tumor size &le;2 cm and &gt;48 months time to relapse. In a retrospective review of 161 patients with an ipsilateral tumor recurrence after initial BCT, patients treated with BCS for recurrent tumors &le;2 cm and &gt;48 months time to relapse had significantly fewer second recurrences compared with tumors &le;2 cm and &lt;48 months time to relapse (15.2 versus 31.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/80\">",
"       80",
"      </a>",
"      ]. In addition, 71.2 percent of patients with tumors &gt;2 cm treated with repeat BCS had a second recurrence, regardless of time to relapse interval.",
"     </li>",
"     <li>",
"      Patients who refuse mastectomy, those with a small recurrent tumor, late relapse, or significant comorbid illnesses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who carry a BRCA1 or BRCA2 deleterious mutation or have an otherwise increased risk of multicentric disease (ie, estrogen receptor negative primary breast cancer, tumor size &gt;3 cm, IBTR detected by physical examination) may not be suitable candidates for repeat BCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/19,83\">",
"     19,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These patients are also candidates for a trial being conducted by the RT Oncology Group (RTOG 1014), which will evaluate the outcomes following repeat BCS followed by partial breast re-irradiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93611563\">",
"    <span class=\"h3\">",
"     BCS alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with repeat BCS had similar outcomes to those who underwent mastectomy, although patients remain at continued risk for a second local recurrence. This is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A retrospective review found no significant difference in five-year disease-free survival for 134 patients treated with a mastectomy or repeat BCS (70 versus 85 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/69\">",
"       69",
"      </a>",
"      ]. However, patients treated with repeat BCS (n=57) were more likely to develop a second local recurrence compared with those treated with mastectomy (19 versus 4 percent).",
"      <br/>",
"     </li>",
"     <li>",
"      In a prospective study of 146 patients with IBTR, there was no significant difference in ten-year survival rates for patients treated with repeat BCS (n = 30) compared with patients treated with mastectomy (58 versus 66 percent), while the 10-year overall survival was 64 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/19\">",
"       19",
"      </a>",
"      ]. Seventy-six women (66 percent) treated by mastectomy met the eligibility criteria for repeat BCS.",
"      <br/>",
"      <br/>",
"      Local recurrence rates were similar for patients treated with repeat BCS and mastectomy (2 of 30 patients [7 percent] versus 8 of 116 patients [7 percent], respectively). Ten years after diagnosis of IBTR, distant metastasis developed in 24 percent of patients treated with BCS and 32 percent of patients treated with mastectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93611571\">",
"    <span class=\"h3\">",
"     BCS plus RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter-based interstitial brachytherapy and standard external beam radiation therapy can be delivered to the previously radiated breast without significant side effects in most patients, and with acceptable cosmesis in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/70,82\">",
"     70,82",
"    </a>",
"    ]. Re-irradiation of the whole breast after repeat BCT is not generally recommended because of the increased risk of normal tissue morbidity (tissue necrosis, rib and lung damage, and for left-sided lesions, cardiac damage).",
"   </p>",
"   <p>",
"    While this approach is not a standard treatment option at most institutions for patients with IBTR following BCT, pilot studies have demonstrated the feasibility and acceptable local rates of repeat BCS with interstitial brachytherapy or partial breast radiation in highly selected women (eg, small size recurrence, relapse &gt;4 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/70,84-87\">",
"     70,84-87",
"    </a>",
"    ]. Local control rates ranged from 57 to 93 percent, with acceptable acute toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/84-88\">",
"     84-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five and 10 year follow-up from prospective studies with interstitial brachytherapy is encouraging. A study of 39 patients with IBTR who underwent a repeat BCS and multi-catheter pulse dose rate (PDR) brachytherapy found the five-year actuarial local control rate was 93 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/82\">",
"     82",
"    </a>",
"    ]. Five-year overall survival and disease-free survival was 87 and 77 percent, respectively. In a series of 11 patients followed for 10 years after repeat BCS and interstitial brachytherapy, 10 women were free of local recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials, with specific eligibility criteria, are needed to determine the optimal approach for patients with IBTR following BCT who may benefit from repeat BCS, with or without additional RT. Optimal radiation dosing and administration technique must also be determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/89-91\">",
"     89-91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE AXILLA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision as to whether to restage the axilla requires multidisciplinary consideration and is best considered in the context of a multidisciplinary tumor board discussion. Factors that must be taken into account include previous axillary surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy, the initial disease stage and likelihood of distant metastases, the recurrence pathology (in situ versus invasive), and the impact that the identification of regional disease will have on adjuvant therapy decisions.",
"   </p>",
"   <p>",
"    The management of the axilla in patients who have an IBTR after BCT is changing because of the increasing use of sentinel lymph node (SLN) biopsy with initial surgery. Prior to the widespread adoption of SLN biopsy, almost all women with an IBTR had already undergone an axillary lymph node dissection (ALND). At present, however, many women with an IBTR will have intact axillary nodes unless the SLN was positive, prompting a completion ALND. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of the regional lymph nodes in breast cancer\", section on 'Axillary dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In older series where the majority of women had undergone ALND as a component of their primary therapy, approximately 18 to 27 percent of patients undergoing axillary exploration for a suspected invasive IBTR had positive nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/16,25,27\">",
"     16,25,27",
"    </a>",
"    ], although rates as high as 50 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/13\">",
"     13",
"    </a>",
"    ]. There are no data describing rates of nodal involvement associated with an IBTR in women who have had a negative SLN biopsy rather than ALND. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Axillary evaluation of the patient with an IBTR should begin with a thorough physical examination and ultrasound of the axilla, with FNA biopsy of any clinically suspicious lymph nodes.",
"   </p>",
"   <p>",
"    For a woman with an IBTR who did not undergo initial ALND, repeat axillary staging with lymphatic mapping and SLN biopsy is reasonable as long as there is no clinical or radiographic evidence of axillary adenopathy. Several studies have shown that SLN biopsy is feasible in women who have undergone prior SLN biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/92-97\">",
"     92-97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no consensus as to optimal management of the axilla in a patient with an IBTR who has already undergone ALND. SLN biopsy in this setting is usually not undertaken because a SLN is frequently not identified and in fact, often maps to the contralateral axilla [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/94\">",
"     94",
"    </a>",
"    ]. Most surgeons explore the axilla at the time of mastectomy, resecting any areas of obvious adenopathy. There is interest in reoperative SLN biopsy after previous ALND is increasing, particularly when lymphoscintigraphy is added to identify sites of nonaxillary drainage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/96,98\">",
"     96,98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     REGIONAL AXILLARY AND SUPRACLAVICULAR RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional nodal recurrences are relatively rare after breast conserving therapy (BCT), occurring in only 1 to 6 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/5,60,99-102\">",
"     5,60,99-102",
"    </a>",
"    ]. Although these rates may increase with the widespread use of sentinel node (SLN) biopsy, early follow-up from uncontrolled reports suggest that local recurrence rates are low in women with a negative SLN who do not undergo completion axillary lymph node dissection (ALND, (",
"    <a class=\"graphic graphic_table graphicRef61866 \" href=\"mobipreview.htm?21/9/21660\">",
"     table 1",
"    </a>",
"    )). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most regional recurrences present as a palpable mass detected on routine follow-up examination. In most series, the axilla is the most commonly involved site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/99,101,103-105\">",
"     99,101,103-105",
"    </a>",
"    ], while others note a higher rate of failure in the supraclavicular nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/5,102,106\">",
"     5,102,106",
"    </a>",
"    ]. This distribution may change with the increasing use of SLN biopsy. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Management of the axilla'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The general approach to the patient with a regional breast cancer recurrence is to rule out distant metastases and whenever possible, resect the area of recurrent disease. Regional nodal recurrences in inoperable sites have a less favorable outcome than those that are potentially resectable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/101,105\">",
"     101,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isolated axillary recurrences are most amenable to treatment and are associated with the best long-term survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/5,99,100,103,104,107\">",
"     5,99,100,103,104,107",
"    </a>",
"    ]. Patients with disease in other nodal regions are highly likely to develop distant metastases, and they have a poor outcome.",
"   </p>",
"   <p>",
"    This can be illustrated by the following two data sets:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report consisted of 165 patients enrolled in one of five NSABP trials who developed a locoregional recurrence other than an IBTR after breast conserving therapy for early breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/5\">",
"       5",
"      </a>",
"      ]. The location of the regional nodal recurrence was axillary only in 47, supraclavicular only in 81, 20 in the chest wall or scar only, and 17 other or multiple local or regional sites. For the entire group, five-year overall and distant disease-free survival rates were 24 and 19 percent, respectively. Patients with an isolated axillary recurrence had a considerably better five-year distant disease-free survival rate than those with a supraclavicular recurrence (32 versus 12 percent, respectively).",
"     </li>",
"     <li>",
"      A smaller series included 39 patients with regional nodal recurrence after BCT, 26 with isolated locoregional disease, and 13 with both regional and distant metastases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/99\">",
"       99",
"      </a>",
"      ]. The location of the regional nodal recurrence was axillary only in 21, supraclavicular only in eight, internal mammary in three, infraclavicular in three, and multiple regional nodes in four. Treatment consisted of surgery in 18, systemic therapy in 34 (as a single modality in 13), and additional radiation therapy (RT) in eight. Sixteen of 21 patients with an isolated axillary recurrence had surgical excision as part of their treatment; three received additional RT.",
"      <br/>",
"      <br/>",
"      Cause-specific survival rates at 5 and 10 years for patients with an isolated locoregional recurrence were 69 and 40 percent, respectively; the corresponding rates for those with a regional plus distant recurrence were 12 percent at both 5 and 10 years. Only eight of the 39 had successful long-term disease control after treatment; the others all had distant metastases at the time of recurrence or developed it subsequently. Of the eight, five remained alive and disease-free, all of whom had isolated axillary locoregional recurrences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment of axillary recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal treatment for an axillary regional recurrence has not been well established. However, the possibility of long-term disease-free survival with multimodality treatment is suggested by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outcomes of 28 patients with an isolated axillary nodal recurrence after BCT for early stage breast cancer were reported at the 2004 meeting of American Society for Radiation Oncology (ASTRO) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/100\">",
"       100",
"      </a>",
"      ]. Four patients (14 percent) had a simultaneous ipsilateral breast tumor recurrence. Local therapy consisted of axillary surgery alone in 16, axillary surgery plus RT in nine; treatment was unknown in three. Systemic therapy was administered to 23 patients.",
"      <br/>",
"      <br/>",
"      In a preliminary report with a median follow-up of 6.2 years after axillary recurrence, 11 (39 percent) had no subsequent recurrence of breast cancer, seven developed a subsequent regional recurrence, and 12 (43 percent) developed distant metastatic disease. Five years after repeat treatment, 56 percent were alive and free of disease recurrence.",
"     </li>",
"     <li>",
"      Another series included 44 patients with an axillary recurrence as the initial treatment failure site; 30 isolated to the axilla, 12 with axillary plus other locoregional recurrence, and two with axillary plus distant recurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/101\">",
"       101",
"      </a>",
"      ]. Treatment consisted of surgical resection in 20, irradiation in two, chemotherapy in 20, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      in two. Multimodality therapy was given to 33 patients (75 percent), and nine patients received systemic therapy alone.",
"      <br/>",
"      <br/>",
"      At an average 27 months posttreatment follow-up, complete and durable local control was achieved in 31 (71 percent), but distant metastases developed in 22 (50 percent). Patients who had locally uncontrolled recurrences were significantly more likely to develop distant metastases (77 versus 39 percent, respectively). Patients who received surgery as a component of therapy were more likely to have locally controlled disease (89 versus 41 percent). In contrast, omission of RT or systemic therapy did not correlate with control of disease or rates of distant metastases.",
"     </li>",
"     <li>",
"      In another retrospective series of 59 patients with an axillary recurrence after surgery for operable breast cancer, 41 of whom received surgery, the five-year actuarial survival rate was 39 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is not enough evidence to define the optimal treatment for patients with an isolated axillary regional recurrence, and practice is variable. However, multidisciplinary evaluation and management is essential.",
"   </p>",
"   <p>",
"    If there is no evidence of distant metastatic spread, every attempt should be made to resect the recurrent disease. For patients who had an initially negative SLN biopsy but who now have an axillary recurrence, a complete axillary lymph node dissection (levels I and II) is indicated. For patients who have not previously received regional nodal irradiation, RT is often recommended, although there are no data proving benefit for RT after ALND in this setting, and lymphedema rates may be significantly higher when an ALND is followed by RT. Because of these issues, some institutions withhold RT unless the area of disease recurrence cannot be completely resected.",
"   </p>",
"   <p>",
"    For patients who have an axillary recurrence after a prior ALND, an attempt at resection is warranted. Local outcomes seem to be most favorable when resection is followed by RT, with or without systemic therapy, likely because of incomplete resection in such cases. For patients who have previously undergone regional irradiation, systemic therapy alone is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Treatment of isolated supraclavicular recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM staging classification for breast cancer considers supraclavicular disease as N3 involvement rather than a metastatic (M) site. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite this, there is debate as to whether patients with isolated supraclavicular relapse should be considered as having disseminated disease or locoregional disease for which aggressive treatment with curative intent is justified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/109\">",
"     109",
"    </a>",
"    ]. Outcomes are less favorable for patients with an isolated supraclavicular as compared to axillary regional recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/110\">",
"     110",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of locoregional recurrence of breast cancer after mastectomy\", section on 'Prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of the published data on treatment and outcomes among women with ipsilateral isolated supraclavicular node recurrences after either mastectomy or breast conserving therapy come from retrospective analyses; there are no randomized trials. These data are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=see_link&amp;anchor=H26#H26\">",
"     \"Management of locoregional recurrence of breast cancer after mastectomy\", section on 'Isolated supraclavicular recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Taken together, the data support the view that while the presence of supraclavicular nodal disease heralds a poor prognosis, a small number of patients who present with isolated supraclavicular nodal relapse will have a prolonged period of disease-free survival after multimodality therapy; and some may be cured. The optimal treatment for these patients has not been established. However, multidisciplinary evaluation and management is essential.",
"   </p>",
"   <p>",
"    For patients who are considered candidates for systemic therapy, initial systemic therapy is preferred. At the time of restaging, if there is still no evidence of distant metastatic spread, surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT could be considered for disease control, depending on the magnitude of the response, the volume of residual disease, as well as the expected morbidity of both therapies. RT alone may be used if the area was not previously irradiated, surgery alone if RT was previously given, or a combination approach if there has been an incomplete response to chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=see_link&amp;anchor=H26#H26\">",
"     \"Management of locoregional recurrence of breast cancer after mastectomy\", section on 'Isolated supraclavicular recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ROLE OF SYSTEMIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who develop an isolated locoregional recurrence after primary treatment for operable breast cancer, systemic treatment alone does not provide durable disease control, and it is not an acceptable substitute for adequate local therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/111,112\">",
"     111,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An unresolved question is whether systemic therapy should be administered in addition to locoregional treatment to all patients who are treated for a local recurrence after BCT. Given the substantial risk for a subsequent local recurrence or distant metastases, this approach is often recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/12,13,49,111,113-118\">",
"     12,13,49,111,113-118",
"    </a>",
"    ], although the available data supporting this strategy are scant.",
"   </p>",
"   <p>",
"    The only trial that has addressed this issue randomly assigned 167 women with ER-positive or ER-unknown locally recurrent breast cancer, a disease-free interval &gt;12 months after initial mastectomy, and three or fewer nodules, none more than 3 cm in size, to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    until relapse or observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/119\">",
"     119",
"    </a>",
"    ]. All patients underwent complete gross tumor resection followed by 50 Gy RT to \"involved areas\". At a median follow-up of 6.3 years, five-year relapse-free survival rates were significantly greater in the tamoxifen arm (59 versus 36 percent, respectively), but the difference had all but disappeared by nine years. Overall survival was the same in both groups.",
"   </p>",
"   <p>",
"    The results of the few reported retrospective series are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A benefit for hormone therapy but not chemotherapy was suggested in a matched pair analysis of outcomes among 230 patients treated for a locally recurrent breast cancer at a single institution between 1964 and 1986 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/120\">",
"       120",
"      </a>",
"      ]. Each patient treated with RT and systemic chemotherapy or hormone therapy was matched with a control patient who received RT alone.",
"      <br/>",
"      <br/>",
"      The addition of hormone therapy to RT was associated with a significantly better five-year overall survival (50 versus 28 percent), disease-free survival (37 versus 26 percent) and distant metastases-free survival (45 versus 29 percent). However, there was no advantage in terms of locoregional control, and chemotherapy did not confer any benefit.",
"     </li>",
"     <li>",
"      In a retrospective series of 145 patients treated with RT for a postmastectomy locoregional recurrence, chemotherapy was prescribed to 18, while 59 received hormone therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/110\">",
"       110",
"      </a>",
"      ]. While five-year survival rates were similar in the groups who did and did not receive hormone therapy (41 and 43 percent, respectively), they were significantly worse in patients receiving chemotherapy compared to those who did not (8 versus 46 percent). It is likely that this result reflects the selection of patients with poorer prognosis disease to receive chemotherapy.",
"     </li>",
"     <li>",
"      The benefit of eight cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      after locoregional treatment was studied in a retrospective review of 120 chemotherapy-naive patients with postmastectomy locoregional recurrence; outcomes were compared to a nonrandomly assigned but contemporarily treated control cohort who did not receive immediate chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/121\">",
"       121",
"      </a>",
"      ]. At five years, there was a nonsignificant trend towards better distant recurrence free survival (75 versus 61 percent) and overall survival (82 versus 74 percent, respectively) in those receiving immediate chemotherapy.",
"     </li>",
"     <li>",
"      A benefit for systemic therapy in premenopausal but not postmenopausal women was suggested in a retrospective analysis of 105 breast cancer patients with an isolated local recurrence after mastectomy or BCT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/122\">",
"       122",
"      </a>",
"      ]. With median 11.5 year follow-up, the use of either ovarian suppression or chemotherapy significantly decreased the risk of death in premenopausal women; the role of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      could not be ascertained because of the small number of women who received it. In contrast, for postmenopausal women, there was no benefit from either tamoxifen or chemotherapy.",
"     </li>",
"     <li>",
"      A Cochrane review of systemic therapy in women with a locoregional recurrence of breast cancer concluded that there was insufficient evidence to support this practice and recommended that eligible women be enrolled on clinical trials testing the benefit of systemic therapy in this setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of systemic therapy in women treated for an isolated locoregional breast cancer recurrence after BCT remains uncertain, and clinical trials are desperately needed in this area. Guidelines from the National Comprehensive Cancer Network (NCCN) for treatment of women with a locoregional breast cancer recurrence suggest \"consideration of systemic therapy\" after locoregional management, but do not specify the type of therapy or duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally suggest hormone therapy if the disease is hormone responsive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For a postmenopausal woman, we suggest a selective aromatase inhibitor (SAI) if she relapsed while receiving adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , if she has not received any adjuvant endocrine treatment, or if relapse occurred more than one year after discontinuing adjuvant tamoxifen or an SAI. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=see_link\">",
"       \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If the woman relapsed during or within 12 months of receiving an SAI in the adjuvant setting, a SERM such as tamoxifen or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30181?source=see_link\">",
"       toremifene",
"      </a>",
"      represents an appropriate option.",
"     </li>",
"     <li>",
"      For a premenopausal woman, appropriate options include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      or ovarian",
"      <span class=\"nowrap\">",
"       suppression/ablation.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest chemotherapy in conjunction with locoregional treatment for women with hormone receptor-negative recurrent breast cancer. The role of chemotherapy in addition to hormone therapy for women with hormone-responsive tumors is uncertain, and we suggest that eligible patients be offered enrollment on the randomized trial described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/124\">",
"     124",
"    </a>",
"    ]. Otherwise, treatment recommendations must be individualized according to the patient's circumstances and desires.",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for patients who have locoregional recurrent disease with HER2-overexpressing tumors is also not settled. However, in view of the significant benefit of adjuvant trastuzumab in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and taxane-based chemotherapy in women treated for earlier stage high-risk disease, we suggest a course of therapy in women who did not receive it in the adjuvant setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Induction therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases systemic therapy will be considered following locoregional therapy. However, systemic therapy represents appropriate initial therapy in certain circumstances. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial trial of systemic therapy in patients who have an apparently isolated supraclavicular nodal recurrence can help to identify those patients with early distant dissemination, in whom locoregional therapy might not provide the potential for long-term relapse-free survival. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment of isolated supraclavicular recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with locally fixed or large tumors or a recurrence that involves the skin, particularly if it is inflammatory, induction systemic therapy is usually administered prior to definitive locoregional therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/45,48,62\">",
"       45,48,62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Diagnosis and pretreatment evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Between 10 and 20 percent of patients will develop a locoregional recurrence within 10 years of undergoing breast conserving therapy (BCT) for operable breast cancer. Rates are substantially higher in women who do not receive radiation therapy (RT) as a component of BCT. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      The median interval to develop a locoregional recurrence after BCT is three to four years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence and characteristics'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      IBTRs are generally detected either by finding a palpable mass on physical examination or as a change on surveillance mammography. Any change in the examination more than one or two years after completion of RT must be viewed as suspicious for recurrence. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis and pretreatment evaluation'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      The diagnostic evaluation of a patient with a suspected locoregional recurrence after BCT should include a full staging workup to exclude the presence of distant metastases. Biopsy is warranted to confirm the disease recurrence and to test for expression of hormone receptors and HER2. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Staging workup'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with a locoregional recurrence after BCT is complex and usually requires a combined modality approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Isolated in breast recurrence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      We recommend a mastectomy for women with an ipsilateral breast tumor recurrence (IBTR) following breast conserving therapy (BCT &ndash; breast conserving surgery and radiation therapy), without evidence of distant disease, and a high likelihood of multicentric disease (eg, carriers of a deleterious BRCA1 or BRCA2 mutation, estrogen receptor negative primary breast cancer, or local recurrence greater than 3 cm) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Mastectomy'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      For women with an IBTR following BCT and who have a low likelihood of multicentric disease, we recommend a mastectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Mastectomy'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      An alternative to mastectomy is repeat breast conserving surgery (BCS), with or without interstitial brachytherapy or partial breast radiation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Breast conserving surgery'",
"      </a>",
"      above.) This approach is best reserved for the patient who refuses mastectomy, has significant comorbid illnesses, or has enrolled in a clinical study.",
"      <br/>",
"     </li>",
"     <li>",
"      For the patient who develops an IBTR after BCS without whole breast irradiation, we suggest repeat BCS followed by radiation therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Breast conserving surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=see_link\">",
"       \"Breast conserving therapy\"",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      The need for repeat surgical staging of the axilla if an axillary lymph node dissection (ALND) was previously performed is controversial, and there is no consensus as to the optimal approach. In the absence of clinical or radiographic evidence of axillary disease, SLN biopsy may be considered. For the patient with clinical evidence of axillary disease, we recommend surgical resection when feasible. (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management of the axilla'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      At the time of mastectomy, we suggest repeat axillary staging with lymphatic mapping and SLN biopsy for a woman who did not undergo initial axillary lymph node dissection (ALND) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management of the axilla'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If there is evidence of skin involvement or an inflammatory type of recurrence that precludes a mastectomy, we suggest initial systemic therapy followed by locoregional therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Mastectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Role of systemic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H859027629\">",
"    <span class=\"h3\">",
"     Axillary regional recurrence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For patients with an isolated axillary recurrence who have not previously undergone an axillary lymph node dissection (ALND), we suggest ALND (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If a prior ALND was performed, we suggest resection (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"     </li>",
"     <li>",
"      The benefit of RT after ALND for patients who have not previously received regional nodal irradiation is unclear, and there is no consensus as to whether it should be recommended after a complete resection. We suggest postoperative radiation therapy if a complete resection is not possible",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      for those patients who develop an axillary recurrence after a prior ALND (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Regional axillary and supraclavicular recurrence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Supraclavicular regional recurrence",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with an isolated supraclavicular recurrence without distant metastases should be approached with curative intent. For patients who are candidates for systemic therapy, we suggest initial systemic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If restaging reveals no distant spread, subsequent local therapy (surgery",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT, or a combination approach) depends upon the degree of response, the volume of residual tumor, and the expected morbidity of each modality. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment of isolated supraclavicular recurrence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Role of systemic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Although it is commonly recommended, the benefit of systemic therapy is uncertain. We prefer that eligible women be offered enrollment on the randomized trial testing the value of chemotherapy after resection of a locoregional recurrence (IBCSG 27-02, BIG 1-02, NSABP B-37) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/53/34650/abstract/124,125\">",
"       124,125",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"     <li>",
"      For women who are not eligible or who decline participation, we suggest hormone therapy for those with hormone receptor-positive locoregional recurrent disease, chemotherapy for those with hormone receptor-negative disease, and a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      -containing chemotherapy regimen for those with HER2-positive disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Role of systemic therapy'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      In most cases, systemic therapy is administered following locoregional therapy. However, in some circumstances (eg, an apparently isolated supraclavicular recurrence, an in-breast recurrence that is large, involves the skin, or inflammatory), an initial trial of systemic therapy is preferred. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Treatment of isolated supraclavicular recurrence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/1\">",
"      Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/2\">",
"      Newman EA, Guest AB, Helvie MA, et al. Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer 2006; 107:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/3\">",
"      Fisher B, Costantino J, Redmond C, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/4\">",
"      Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/5\">",
"      Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 2006; 24:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/6\">",
"      Kontos M, Roy P, Rizos D, Hamed H. An evidence based strategy for follow up after breast conserving treatment for breast cancer. J Surg Oncol 2011; 104:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/7\">",
"      van Tienhoven G, Voogd AC, Peterse JL, et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer 1999; 35:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/8\">",
"      Haffty BG, Carter D, Flynn SD, et al. Local recurrence versus new primary: clinical analysis of 82 breast relapses and potential applications for genetic fingerprinting. Int J Radiat Oncol Biol Phys 1993; 27:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/9\">",
"      Voogd AC, van Oost FJ, Rutgers EJ, et al. Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer 2005; 41:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/10\">",
"      Francis M, Cakir B, Ung O, et al. Prognosis after breast recurrence following conservative surgery and radiotherapy in patients with node-negative breast cancer. Br J Surg 1999; 86:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/11\">",
"      Dalberg K, Mattsson A, Sandelin K, Rutqvist LE. Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer. Breast Cancer Res Treat 1998; 49:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/12\">",
"      Pisansky TM, Ingle JN, Schaid DJ, et al. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. Cancer 1993; 72:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/13\">",
"      Hsi RA, Antell A, Schultz DJ, Solin LJ. Radiation therapy for chest wall recurrence of breast cancer after mastectomy in a favorable subgroup of patients. Int J Radiat Oncol Biol Phys 1998; 42:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/14\">",
"      Chauvet B, Reynaud-Bougnoux A, Calais G, et al. Prognostic significance of breast relapse after conservative treatment in node-negative early breast cancer. Int J Radiat Oncol Biol Phys 1990; 19:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/15\">",
"      Fowble B, Solin LJ, Schultz DJ, et al. Breast recurrence following conservative surgery and radiation: patterns of failure, prognosis, and pathologic findings from mastectomy specimens with implications for treatment. Int J Radiat Oncol Biol Phys 1990; 19:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/16\">",
"      Abner AL, Recht A, Eberlein T, et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1993; 11:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/17\">",
"      Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/18\">",
"      Fredriksson I, Liljegren G, Arnesson LG, et al. Local recurrence in the breast after conservative surgery--a study of prognosis and prognostic factors in 391 women. Eur J Cancer 2002; 38:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/19\">",
"      Alpert TE, Kuerer HM, Arthur DW, et al. Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys 2005; 63:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/20\">",
"      Huang E, Buchholz TA, Meric F, et al. Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences. Cancer 2002; 95:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/21\">",
"      Smith TE, Lee D, Turner BC, et al. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 2000; 48:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/22\">",
"      Veronesi U, Marubini E, Del Vecchio M, et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995; 87:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/23\">",
"      Yi M, Buchholz TA, Meric-Bernstam F, et al. Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning. Ann Surg 2011; 253:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/24\">",
"      Fortin A, Larochelle M, Laverdi&egrave;re J, et al. Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol 1999; 17:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/25\">",
"      Voogd AC, van Tienhoven G, Peterse HL, et al. Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Dutch Study Group on Local Recurrence after Breast Conservation (BORST). Cancer 1999; 85:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/26\">",
"      Kurtz JM, Spitalier JM, Amalric R, et al. The prognostic significance of late local recurrence after breast-conserving therapy. Int J Radiat Oncol Biol Phys 1990; 18:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/27\">",
"      Meijer-van Gelder ME, Look MP, Bolt-de Vries J, et al. Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse. J Clin Oncol 1999; 17:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/28\">",
"      Vicini FA, Antonucci JV, Goldstein N, et al. The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy. Cancer 2007; 109:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/29\">",
"      Bollet MA, Servant N, Neuvial P, et al. High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers. J Natl Cancer Inst 2008; 100:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/30\">",
"      Smitt MC, Nowels KW, Zdeblick MJ, et al. The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer 1995; 76:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/31\">",
"      Dershaw DD, McCormick B, Osborne MP. Detection of local recurrence after conservative therapy for breast carcinoma. Cancer 1992; 70:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/32\">",
"      Solin LJ, Fourquet A, Vicini FA, et al. Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast. Cancer 2001; 91:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/33\">",
"      Weng EY, Juillard GJ, Parker RG, et al. Outcomes and factors impacting local recurrence of ductal carcinoma in situ. Cancer 2000; 88:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/34\">",
"      Montgomery DA, Krupa K, Jack WJ, et al. Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. Br J Cancer 2007; 96:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/35\">",
"      Montgomery DA, Krupa K, Cooke TG. Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer 2007; 97:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/36\">",
"      Mumtaz H, Davidson T, Hall-Craggs MA, et al. Comparison of magnetic resonance imaging and conventional triple assessment in locally recurrent breast cancer. Br J Surg 1997; 84:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/37\">",
"      Dao TH, Rahmouni A, Campana F, et al. Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 187:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/38\">",
"      Belli P, Costantini M, Romani M, et al. Magnetic resonance imaging in breast cancer recurrence. Breast Cancer Res Treat 2002; 73:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/39\">",
"      Rieber A, Schramm K, Helms G, et al. Breast-conserving surgery and autogenous tissue reconstruction in patients with breast cancer: efficacy of MRI of the breast in the detection of recurrent disease. Eur Radiol 2003; 13:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/40\">",
"      Kr&auml;mer S, Schulz-Wendtland R, Hagedorn K, et al. Magnetic resonance imaging in the diagnosis of local recurrences in breast cancer. Anticancer Res 1998; 18:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/41\">",
"      Mu&uuml;ller RD, Barkhausen J, Sauerwein W, Langer R. Assessment of local recurrence after breast-conserving therapy with MRI. J Comput Assist Tomogr 1998; 22:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/42\">",
"      Teifke A, Lehr HA, Vomweg TW, et al. Outcome analysis and rational management of enhancing lesions incidentally detected on contrast-enhanced MRI of the breast. AJR Am J Roentgenol 2003; 181:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/43\">",
"      Drew PJ, Kerin MJ, Turnbull LW, et al. Routine screening for local recurrence following breast-conserving therapy for cancer with dynamic contrast-enhanced magnetic resonance imaging of the breast. Ann Surg Oncol 1998; 5:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/44\">",
"      Heywang-K&ouml;brunner SH, Schlegel A, Beck R, et al. Contrast-enhanced MRI of the breast after limited surgery and radiation therapy. J Comput Assist Tomogr 1993; 17:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/45\">",
"      Nomura M, Inoue Y, Fujita S, et al. Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery. Breast Cancer 2005; 12:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/46\">",
"      Kurtz JM, Jacquemier J, Brandone H, et al. Inoperable recurrence after breast-conserving surgical treatment and radiotherapy. Surg Gynecol Obstet 1991; 172:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/47\">",
"      Gage I, Schnitt SJ, Recht A, et al. Skin recurrences after breast-conserving therapy for early-stage breast cancer. J Clin Oncol 1998; 16:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/48\">",
"      Huston TL, Simmons RM. Inflammatory local recurrence after breast-conservation therapy for noninflammatory breast cancer. Am J Clin Oncol 2005; 28:431.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/50\">",
"      Lindfors KK, Meyer JE, Busse PM, et al. CT evaluation of local and regional breast cancer recurrence. AJR Am J Roentgenol 1985; 145:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/51\">",
"      Rosenman J, Churchill CA, Mauro MA, et al. The role of computed tomography in the evaluation of post-mastectomy locally recurrent breast cancer. Int J Radiat Oncol Biol Phys 1988; 14:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/52\">",
"      Lingawi SS, Bilbey JH, Munk PL, et al. MR imaging of brachial plexopathy in breast cancer patients without palpable recurrence. Skeletal Radiol 1999; 28:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/53\">",
"      Radan L, Ben-Haim S, Bar-Shalom R, et al. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 2006; 107:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/54\">",
"      Eubank WB, Mankoff D, Bhattacharya M, et al. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004; 183:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/55\">",
"      Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 2003; 38:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/56\">",
"      Eubank WB, Mankoff DA, Takasugi J, et al. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001; 19:3516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/57\">",
"      Bender H, Kirst J, Palmedo H, et al. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997; 17:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/58\">",
"      Constantinidou A, Martin A, Sharma B, Johnston SR. Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol 2011; 22:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/59\">",
"      Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 2005; 90:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/60\">",
"      Leung S, Otmezguine Y, Calitchi E, et al. Locoregional recurrences following radical external beam irradiation and interstitial implantation for operable breast cancer--a twenty three year experience. Radiother Oncol 1986; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/61\">",
"      Recht A, Schnitt SJ, Connolly JL, et al. Prognosis following local or regional recurrence after conservative surgery and radiotherapy for early stage breast carcinoma. Int J Radiat Oncol Biol Phys 1989; 16:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/62\">",
"      Easson AM, McCready DR. Management of local recurrence of breast cancer. Expert Rev Anticancer Ther 2004; 4:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/63\">",
"      Osborne MP, Borgen PI, Wong GY, et al. Salvage mastectomy for local and regional recurrence after breast-conserving operation and radiation therapy. Surg Gynecol Obstet 1992; 174:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/64\">",
"      Haffty BG, Fischer D, Beinfield M, McKhann C. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 1991; 21:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/65\">",
"      Orel SG, Fowble BL, Solin LJ, et al. Breast cancer recurrence after lumpectomy and radiation therapy for early-stage disease: prognostic significance of detection method. Radiology 1993; 188:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/66\">",
"      Galper S, Blood E, Gelman R, et al. Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2005; 61:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/67\">",
"      Doyle T, Schultz DJ, Peters C, et al. Long-term results of local recurrence after breast conservation treatment for invasive breast cancer. Int J Radiat Oncol Biol Phys 2001; 51:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/68\">",
"      Shen J, Hunt KK, Mirza NQ, et al. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer 2005; 104:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/69\">",
"      Salvadori B, Marubini E, Miceli R, et al. Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery. Br J Surg 1999; 86:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/70\">",
"      Kuerer HM, Arthur DW, Haffty BG. Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence: the potential role of partial breast irradiation. Cancer 2004; 100:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/71\">",
"      Cajucom CC, Tsangaris TN, Nemoto T, et al. Results of salvage mastectomy for local recurrence after breast-conserving surgery without radiation therapy. Cancer 1993; 71:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/72\">",
"      Meric F, Mirza NQ, Vlastos G, et al. Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer 2003; 97:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/73\">",
"      Solin LJ, Fourquet A, Vicini FA, et al. Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situ. Eur J Cancer 2005; 41:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/74\">",
"      Halverson KJ, Perez CA, Kuske RR, et al. Survival following locoregional recurrence of breast cancer: univariate and multivariate analysis. Int J Radiat Oncol Biol Phys 1992; 23:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/75\">",
"      Whelan T, Clark R, Roberts R, et al. Ipsilateral breast tumor recurrence postlumpectomy is predictive of subsequent mortality: results from a randomized trial. Investigators of the Ontario Clinical Oncology Group. Int J Radiat Oncol Biol Phys 1994; 30:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/76\">",
"      Haffty BG, Reiss M, Beinfield M, et al. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol 1996; 14:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/77\">",
"      Panet-Raymond V, Truong PT, Alexander C, et al. Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence. Cancer 2011; 117:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/78\">",
"      van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000; 92:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/79\">",
"      Komoike Y, Motomura K, Inaji H, et al. Repeat lumpectomy for patients with ipsilateral breast tumor recurrence after breast-conserving surgery. Preliminary results. Oncology 2003; 64:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/80\">",
"      Gentilini O, Botteri E, Veronesi P, et al. Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates. Ann Surg Oncol 2012; 19:3771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/81\">",
"      McCready DR, Fish EB, Hiraki GY, et al. Total mastectomy is not always mandatory for the treatment of recurrent breast cancer after lumpectomy alone. Can J Surg 1992; 35:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/82\">",
"      Kauer-Dorner D, P&ouml;tter R, Resch A, et al. Partial breast irradiation for locally recurrent breast cancer within a second breast conserving treatment: alternative to mastectomy? Results from a prospective trial. Radiother Oncol 2012; 102:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/83\">",
"      Gentilini O, Botteri E, Rotmensz N, et al. When can a second conservative approach be considered for ipsilateral breast tumour recurrence? Ann Oncol 2007; 18:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/84\">",
"      Resch A, Fellner C, Mock U, et al. Locally recurrent breast cancer: pulse dose rate brachytherapy for repeat irradiation following lumpectomy-- a second chance to preserve the breast. Radiology 2002; 225:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/85\">",
"      Deutsch M. Repeat high-dose external beam irradiation for in-breast tumor recurrence after previous lumpectomy and whole breast irradiation. Int J Radiat Oncol Biol Phys 2002; 53:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/86\">",
"      Maulard C, Housset M, Brunel P, et al. Use of perioperative or split-course interstitial brachytherapy techniques for salvage irradiation of isolated local recurrences after conservative management of breast cancer. Am J Clin Oncol 1995; 18:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/87\">",
"      Wahl AO, Rademaker A, Kiel KD, et al. Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. Int J Radiat Oncol Biol Phys 2008; 70:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/88\">",
"      Guix B, Lej&aacute;rcegui JA, Tello JI, et al. Exeresis and brachytherapy as salvage treatment for local recurrence after conservative treatment for breast cancer: results of a ten-year pilot study. Int J Radiat Oncol Biol Phys 2010; 78:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/89\">",
"      Hannoun-Levi JM, Houvenaeghel G, Ellis S, et al. Partial breast irradiation as second conservative treatment for local breast cancer recurrence. Int J Radiat Oncol Biol Phys 2004; 60:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/90\">",
"      Trombetta M, Julian T, Bhandari T, et al. Breast conservation surgery and interstitial brachytherapy in the management of locally recurrent carcinoma of the breast: the Allegheny General Hospital experience. Brachytherapy 2008; 7:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/91\">",
"      Chadha M, Feldman S, Boolbol S, et al. The feasibility of a second lumpectomy and breast brachytherapy for localized cancer in a breast previously treated with lumpectomy and radiation therapy for breast cancer. Brachytherapy 2008; 7:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/92\">",
"      Intra M, Trifir&ograve; G, Viale G, et al. Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy. Ann Surg Oncol 2005; 12:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/93\">",
"      Taback B, Nguyen P, Hansen N, et al. Sentinel lymph node biopsy for local recurrence of breast cancer after breast-conserving therapy. Ann Surg Oncol 2006; 13:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/94\">",
"      Newman EA, Cimmino VM, Sabel MS, et al. Lymphatic mapping and sentinel lymph node biopsy for patients with local recurrence after breast-conservation therapy. Ann Surg Oncol 2006; 13:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/95\">",
"      Boughey JC, Ross MI, Babiera GV, et al. Sentinel lymph node surgery in locally recurrent breast cancer. Clin Breast Cancer 2006; 7:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/96\">",
"      Port ER, Garcia-Etienne CA, Park J, et al. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence. Ann Surg Oncol 2007; 14:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/97\">",
"      Cox CE, Furman BT, Kiluk JV, et al. Use of reoperative sentinel lymph node biopsy in breast cancer patients. J Am Coll Surg 2008; 207:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/98\">",
"      Newman LA. Lymphatic mapping and sentinel lymph node biopsy for locally recurrent breast cancer: new clues to understanding the biology of chest wall relapse. Ann Surg Oncol 2007; 14:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/99\">",
"      Harris EE, Hwang WT, Seyednejad F, Solin LJ. Prognosis after regional lymph node recurrence in patients with stage I-II breast carcinoma treated with breast conservation therapy. Cancer 2003; 98:2144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/100\">",
"      Galper S, Blood E, Gelman R, et al. Prognosis after isolated axillary nodal recurrence following conservative surgery and radiotherapy for early-stage breast carcinoma (abstract). Int J Radiat Oncol Biol Phys 2002; 54(2 suppl):56s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/101\">",
"      Newman LA, Hunt KK, Buchholz T, et al. Presentation, management and outcome of axillary recurrence from breast cancer. Am J Surg 2000; 180:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/102\">",
"      Fodor J, Toth J, Major T, et al. Incidence and time of occurrence of regional recurrence in stage I-II breast cancer: value of adjuvant irradiation. Int J Radiat Oncol Biol Phys 1999; 44:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/103\">",
"      Halverson KJ, Perez CA, Kuske RR, et al. Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. Int J Radiat Oncol Biol Phys 1990; 19:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/104\">",
"      Fowble B, Solin LJ, Schultz DJ, Goodman RL. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys 1989; 17:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/105\">",
"      Moran MS, Haffty BG. Local-regional breast cancer recurrence: prognostic groups based on patterns of failure. Breast J 2002; 8:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/106\">",
"      Vicini FA, Horwitz EM, Lacerna MD, et al. The role of regional nodal irradiation in the management of patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 1997; 39:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/107\">",
"      Recht A, Pierce SM, Abner A, et al. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol 1991; 9:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/108\">",
"      de Boer R, Hillen HF, Roumen RM, et al. Detection, treatment and outcome of axillary recurrence after axillary clearance for invasive breast cancer. Br J Surg 2001; 88:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/109\">",
"      Jagsi R. Breast cancer in the supraclavicular region: is the horse out of the barn? Breast Cancer Res Treat 2011; 125:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/110\">",
"      Willner J, Kiricuta IC, K&ouml;lbl O. Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. Int J Radiat Oncol Biol Phys 1997; 37:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/111\">",
"      Beck TM, Hart NE, Woodard DA, Smith CE. Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients. J Clin Oncol 1983; 1:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/112\">",
"      Hoogstraten B, Gad-el-Mawla N, Maloney TR, et al. Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study. Cancer 1984; 54:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/113\">",
"      Harris JR, Halpin-Murphy P, McNeese M, et al. Consensus Statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/114\">",
"      Clemons M, Hamilton T, Mansi J, et al. Management of recurrent locoregional breast cancer: oncologist survey. Breast 2003; 12:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/115\">",
"      Eek RW, Falkson CI. Extended survival in 80 patients with operable, locoregionally recurrent breast cancer treated with chemotherapy. Am J Clin Oncol 1998; 21:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/116\">",
"      Ballo MT, Strom EA, Prost H, et al. Local-regional control of recurrent breast carcinoma after mastectomy: does hyperfractionated accelerated radiotherapy improve local control? Int J Radiat Oncol Biol Phys 1999; 44:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/117\">",
"      Stefanik D, Goldberg R, Byrne P, et al. Local-regional failure in patients treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1985; 3:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/118\">",
"      Freedman GM, Fowble BL. Local recurrence after mastectomy or breast-conserving surgery and radiation. Oncology (Williston Park) 2000; 14:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/119\">",
"      Borner M, Bacchi M, Goldhirsch A, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol 1994; 12:2071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/120\">",
"      Halverson KJ, Perez CA, Kuske RR, et al. Locoregional recurrence of breast cancer: a retrospective comparison of irradiation alone versus irradiation and systemic therapy. Am J Clin Oncol 1992; 15:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/121\">",
"      Haylock BJ, Coppin CM, Jackson J, et al. Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy. Int J Radiat Oncol Biol Phys 2000; 46:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/122\">",
"      L&ecirc; MG, Arriagada R, Spielmann M, et al. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer 2002; 94:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/123\">",
"      Rauschecker H, Clarke M, Gatzemeier W, Recht A. Systemic therapy for treating locoregional recurrence in women with breast cancer. Cochrane Database Syst Rev 2001; :CD002195.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical Trial information available www.cancer.gov/clinicaltrials/IBCSG-27-02 (Accessed on March 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/53/34650/abstract/125\">",
"      Wapnir IL, Aebi S, Gelber S, et al. Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer. Ann Surg Oncol 2008; 15:3227.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 765 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34650=[""].join("\n");
var outline_f33_53_34650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE AND CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      True recurrence versus second primary tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS FOR A LOCAL RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Importance of RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Margin status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS AND PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Presenting signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Staging workup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93609717\">",
"      MANAGEMENT OF THE BREAST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Local regional control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93611195\">",
"      - Outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - RT after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Breast conserving surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93611563\">",
"      - BCS alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93611571\">",
"      - BCS plus RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT OF THE AXILLA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      REGIONAL AXILLARY AND SUPRACLAVICULAR RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment of axillary recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Treatment of isolated supraclavicular recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ROLE OF SYSTEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Induction therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Diagnosis and pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Isolated in breast recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H859027629\">",
"      - Axillary regional recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Supraclavicular regional recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Role of systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/765\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/765|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/9/21660\" title=\"table 1\">",
"      Axillary recur neg SLN biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/43/37561?source=related_link\">",
"      Ductal carcinoma in situ: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19194?source=related_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8202?source=related_link\">",
"      Patterns of relapse and long-term complications of therapy in breast cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=related_link\">",
"      Tumor node metastasis (TNM) staging classification for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_53_34651="Pulm mets surgery";
var content_f33_53_34651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Surgical approaches for resection of pulmonary metastases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Procedure",
"      </td>",
"      <td class=\"subtitle1\">",
"       Pain",
"      </td>",
"      <td class=\"subtitle1\">",
"       Exposure",
"      </td>",
"      <td class=\"subtitle1\">",
"       Lung palpation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Postoperative respiratory compromise",
"      </td>",
"      <td class=\"subtitle1\">",
"       Wound complication",
"      </td>",
"      <td class=\"subtitle1\">",
"       Adhesions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       VATS",
"      </td>",
"      <td>",
"       (+)",
"      </td>",
"      <td>",
"       (++)",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       (+)",
"      </td>",
"      <td>",
"       (+)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Thoracotomy",
"      </td>",
"      <td>",
"       (+++)",
"      </td>",
"      <td>",
"       (+++)",
"      </td>",
"      <td>",
"       (+++)",
"      </td>",
"      <td>",
"       (+++)",
"      </td>",
"      <td>",
"       (+)",
"      </td>",
"      <td>",
"       (+++)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sternotomy",
"      </td>",
"      <td>",
"       (++)",
"      </td>",
"      <td>",
"       (+)",
"      </td>",
"      <td>",
"       (+++)",
"      </td>",
"      <td>",
"       (+)",
"      </td>",
"      <td>",
"       (++)*",
"      </td>",
"      <td>",
"       (+++)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clamshell",
"      </td>",
"      <td>",
"       (++++)",
"      </td>",
"      <td>",
"       (++++)",
"      </td>",
"      <td>",
"       (++++)",
"      </td>",
"      <td>",
"       (++++)",
"      </td>",
"      <td>",
"       (++)*",
"      </td>",
"      <td>",
"       (+++)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     VATS: video-assisted thoracoscopic surgery.",
"     <br>",
"      * Related to morbidity not incidence of sternal wound infection.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34651=[""].join("\n");
var outline_f33_53_34651=null;
var title_f33_53_34652="Radiography mediastinal masses";
var content_f33_53_34652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Computed tomography (CT) and magnetic resonance imaging (MRI) in the evaluation of mediastinal masses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            CT superior",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spatial resolution",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Detection of calcification",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Detection",
"of bony destruction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Detection of lung nodules",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Evaluation of lung",
"parenchyma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Single study screening for lung, liver, and adrenal",
"metastases",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            MRI superior",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiplanar imaging capability",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Identification of",
"complex fluid collections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            No IV contrast needed",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Potential for cardiac gating",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Soft",
"tissue differentiation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tumor vs. fibrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tumor vs. postobstructive pneumonitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Evaluation of:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Brachial plexus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Neural foramina",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Diaphragm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Bone marrow",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mediastinal tissue invasion",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            CT and MRI equal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Detection of pure fluid collections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Detection of chest",
"wall invasion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Evaluation of vascular obstruction (contrast CT)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from More, EH. Radiologic Evaluations of Mediastinal Masses. Chest Surg Clin N Am 1992; 2(1). Copyright &copy;1992 WB Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34652=[""].join("\n");
var outline_f33_53_34652=null;
var title_f33_53_34653="COG risk strata neuroblast";
var content_f33_53_34653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Children's Oncology Group neuroblastoma risk strata",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Risk",
"      </td>",
"      <td class=\"subtitle1\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Age",
"      </td>",
"      <td class=\"subtitle1\">",
"       MYCN status",
"      </td>",
"      <td class=\"subtitle1\">",
"       DNA ploidy",
"      </td>",
"      <td class=\"subtitle1\">",
"       INPC",
"      </td>",
"      <td class=\"subtitle1\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"3\">",
"       Low*",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2a/2b",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Not amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Resection &ge;50 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4s",
"      </td>",
"      <td>",
"       &lt;365 days",
"      </td>",
"      <td>",
"       Not amp",
"      </td>",
"      <td>",
"       DI &gt;1",
"      </td>",
"      <td>",
"       FH",
"      </td>",
"      <td>",
"       Asymptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"9\">",
"       Intermediate&bull;",
"      </td>",
"      <td>",
"       2a/2b",
"      </td>",
"      <td>",
"       0-12 years",
"      </td>",
"      <td>",
"       Not amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Biopsy or resection &lt;50 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       &lt;547 days",
"      </td>",
"      <td>",
"       Not amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       &ge;547 days - 12 years",
"      </td>",
"      <td>",
"       Not amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       FH",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       &lt;365 days",
"      </td>",
"      <td>",
"       Not amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       365 - &lt;547 days",
"      </td>",
"      <td>",
"       Not amp",
"      </td>",
"      <td>",
"       DI &gt;1",
"      </td>",
"      <td>",
"       FH",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4s",
"      </td>",
"      <td>",
"       &lt;365 days",
"      </td>",
"      <td>",
"       Not amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Symptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4s",
"      </td>",
"      <td>",
"       &lt;365 days",
"      </td>",
"      <td>",
"       Not amp",
"      </td>",
"      <td>",
"       DI = 1",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Asymptomatic or symptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4s",
"      </td>",
"      <td>",
"       &lt;365 days",
"      </td>",
"      <td>",
"       Not amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       UH",
"      </td>",
"      <td>",
"       Asymptomatic or symptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4s",
"      </td>",
"      <td>",
"       &lt;365 days",
"      </td>",
"      <td>",
"       Missing",
"      </td>",
"      <td>",
"       Missing",
"      </td>",
"      <td>",
"       Missing",
"      </td>",
"      <td>",
"       Too sick for biopsy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"9\">",
"       High&Delta;",
"      </td>",
"      <td>",
"       2a/2b",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any degree of resection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       &ge;547 days",
"      </td>",
"      <td>",
"       Not amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       UH",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       &lt;365 days",
"      </td>",
"      <td>",
"       Amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       365 - &lt;547 days",
"      </td>",
"      <td>",
"       Amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       365 - &lt;547 days",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       DI = 1",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       365 - &lt;547 days",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       UH",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       &ge;547 days",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4s",
"      </td>",
"      <td>",
"       &lt;365 days",
"      </td>",
"      <td>",
"       Amp",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Any",
"      </td>",
"      <td>",
"       Asymptomatic or symptomatic",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     INPC: International Neuroblastoma Pathology Classification; FH: favorable histology; UH: unfavorable histology; Amp: amplified; DI: DNA Index.",
"     <br>",
"      * Low risk groups as defined in Children's Oncology Group trial ANBL00B1.",
"      <br>",
"       &bull; Intermediate risk group as defined in Children's Oncology Group trial ANBL0531.",
"       <br>",
"        &Delta; High risk group as defined in the Children's Oncology Group trial ANBL0532.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34653=[""].join("\n");
var outline_f33_53_34653=null;
var title_f33_53_34654="Multiple metatarsal neck fractures";
var content_f33_53_34654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F52841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F52841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple metatarsal neck fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 230px; height: 463px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fractures of the third and fourth distal metatarsal shaft (neck) are indicated by the arrows; the metatarsal heads are angulated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH and James R Clugston, MD, MS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34654=[""].join("\n");
var outline_f33_53_34654=null;
var title_f33_53_34655="Mumps PI";
var content_f33_53_34655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    A child with mumps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mumps is an infection that causes the glands in front of the ears and above the jaw to swell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hviid A, Rubin S, Muhlemann K. Mumps. Lancet 2008; 371:932-44. Copyright &copy; 2008 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_53_34655=[""].join("\n");
var outline_f33_53_34655=null;
